drug1_db stringlengths 7 7 | drug2_db stringlengths 7 7 | drug1_id int64 0 1.69k | drug2_id int64 0 1.69k | drug_pair listlengths 2 2 | drug1_name stringlengths 4 85 | drug2_name stringlengths 4 85 | drug1_desc stringlengths 27 1.09k | drug2_desc stringlengths 27 6.14k | label stringclasses 3
values | label_idx int64 0 2 | all_paths listlengths 1 10 | all_paths_str listlengths 1 10 | path_str stringlengths 0 3.57k |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
DB01169 | DB08899 | 57 | 129 | [
"DDInter120",
"DDInter649"
] | Arsenic trioxide | Enzalutamide | Arsenic trioxide is a chemotherapeutic agent of idiopathic function used to treat leukemia that is unresponsive to first line agents. It is suspected that arsenic trisulfide induces cancer cells to undergo apoptosis. In general, arsenic is known to be a naturally toxic substance capable of eliciting a variety of danger... | Enzalutamide is an androgen receptor (AR) inhibitor for the treatment of castration-resistant prostate cancer (CRPC), both metastatic and non-metastatic. It is a second-generation antiandrogen agent that the FDA approved on August 31, 2012.[L40639, A252667] Although androgen deprivation therapy (ADT) is the first-line ... | Major | 2 | [
[
[
57,
25,
129
]
],
[
[
57,
64,
918
],
[
918,
1,
129
]
],
[
[
57,
6,
8374
],
[
8374,
45,
129
]
],
[
[
57,
62,
1247
],
[
1247,
23,
... | [
[
[
"Arsenic trioxide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Enzalutamide"
]
],
[
[
"Arsenic trioxide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Bicalutamide"
],
[
"Bicalutam... | Arsenic trioxide may lead to a major life threatening interaction when taken with Bicalutamide and Bicalutamide (Compound) resembles Enzalutamide (Compound)
Arsenic trioxide (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Enzalutamide (Compound)
Arsenic trioxide may cause a minor interaction that can limit... |
DB01166 | DB04844 | 477 | 843 | [
"DDInter379",
"DDInter1778"
] | Cilostazol | Tetrabenazine | Cilostazol is a quinolinone derivative and antiplatelet agent with vasodilating properties that has been used in the symptomatic treatment of intermittent claudication in patients with peripheral ischaemia. It is marketed under the brand name Pletal by Otsuka Pharmaceutical Co.. Cilostazol works by inhibiting both prim... | A drug formerly used as an antipsychotic but now used primarily in the symptomatic treatment of various hyperkinetic disorders. It is a monoamine depletor and used as symptomatic treatment of chorea associated with Huntington's disease. FDA approved on August 15, 2008. | Moderate | 1 | [
[
[
477,
24,
843
]
],
[
[
477,
63,
479
],
[
479,
40,
843
]
],
[
[
477,
6,
12523
],
[
12523,
45,
843
]
],
[
[
477,
18,
5901
],
[
5901,
... | [
[
[
"Cilostazol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tetrabenazine"
]
],
[
[
"Cilostazol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Donepezil"
],
[
... | Cilostazol may cause a moderate interaction that could exacerbate diseases when taken with Donepezil and Donepezil (Compound) resembles Tetrabenazine (Compound)
Cilostazol (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Tetrabenazine (Compound)
Cilostazol (Compound) downregulates GJA1 (Gene) and GJA1 (Gene... |
DB01050 | DB08875 | 848 | 1,618 | [
"DDInter900",
"DDInter262"
] | Ibuprofen | Cabozantinib | Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics. The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin. Ibuprofen was finally p... | Cabozantinib was first approved in 2012 and is a non-specific tyrosine kinase inhibitor. It was initially approved in the US under the brand name Cometriq, which is indicated for the treatment of metastatic medullary thyroid cancer. In 2016, a capsule formulation (Cabometyx) was approved for the treatment of advanced r... | Major | 2 | [
[
[
848,
25,
1618
]
],
[
[
848,
63,
723
],
[
723,
24,
1618
]
],
[
[
848,
24,
384
],
[
384,
63,
1618
]
],
[
[
848,
24,
850
],
[
850,
... | [
[
[
"Ibuprofen",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cabozantinib"
]
],
[
[
"Ibuprofen",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aprepitant"
],
[
"Aprepitant... | Ibuprofen may cause a moderate interaction that could exacerbate diseases when taken with Aprepitant and Aprepitant may cause a moderate interaction that could exacerbate diseases when taken with Cabozantinib
Ibuprofen may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib and Idelal... |
DB00564 | DB01229 | 1,236 | 973 | [
"DDInter293",
"DDInter1377"
] | Carbamazepine | Paclitaxel | Carbamazepine, also known as Tegretol, is an anticonvulsant drug and analgesic drug used to control seizures and to treat pain resulting from trigeminal neuralgia. It was initially approved by the FDA in 1965. Aside from the above uses, this drug is also given to control the symptoms of bipolar 1. Interestingly, carbam... | Paclitaxel is a chemotherapeutic agent marketed under the brand name Taxol among others. Used as a treatment for various cancers, paclitaxel is a mitotic inhibitor that was first isolated in 1971 from the bark of the Pacific yew tree which contains endophytic fungi that synthesize paclitaxel. It is available as an intr... | Moderate | 1 | [
[
[
1236,
24,
973
]
],
[
[
1236,
24,
310
],
[
310,
63,
973
]
],
[
[
1236,
6,
7524
],
[
7524,
45,
973
]
],
[
[
1236,
18,
10375
],
[
10375,
... | [
[
[
"Carbamazepine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Paclitaxel"
]
],
[
[
"Carbamazepine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cabazitaxel"
],
... | Carbamazepine may cause a moderate interaction that could exacerbate diseases when taken with Cabazitaxel and Cabazitaxel may cause a moderate interaction that could exacerbate diseases when taken with Paclitaxel
Carbamazepine (Compound) binds CYP3A5 (Gene) and CYP3A5 (Gene) is bound by Paclitaxel (Compound)
Carbamazep... |
DB00649 | DB06186 | 231 | 1,439 | [
"DDInter1710",
"DDInter969"
] | Stavudine | Ipilimumab | A dideoxynucleoside analog that inhibits reverse transcriptase and has in vitro activity against HIV. | Ipilimumab is a fully humanized IgG1 monoclonal antibody that blocks cytotoxic T lymphocyte antigen-4 (CTLA-4). Blocking CTLA-4 removes an inhibitory signal from reducing the activity of T lymphocytes.[A35065,A35080,L12126] Ipilimumab was developed by Bristol-Myers Squibb and Medarex. Ipilimumab was granted FDA approva... | Moderate | 1 | [
[
[
231,
24,
1439
]
],
[
[
231,
63,
912
],
[
912,
24,
1439
]
],
[
[
231,
24,
267
],
[
267,
24,
1439
]
],
[
[
231,
24,
310
],
[
310,
... | [
[
[
"Stavudine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ipilimumab"
]
],
[
[
"Stavudine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Interferon beta-1a"
],
... | Stavudine may cause a moderate interaction that could exacerbate diseases when taken with Interferon beta-1a and Interferon beta-1a may cause a moderate interaction that could exacerbate diseases when taken with Ipilimumab
Stavudine may cause a moderate interaction that could exacerbate diseases when taken with Naltrex... |
DB00604 | DB00927 | 1,425 | 1,559 | [
"DDInter385",
"DDInter712"
] | Cisapride | Famotidine | In many countries (including Canada) cisapride has been either withdrawn or has had its indications limited due to reports about long QT syndrome due to cisapride, which predisposes to arrhythmias. The FDA issued a warning letter regarding this risk to health care professionals and patients. | Famotidine is a competitive histamine-2 (H<sub>2</sub>) receptor antagonist that works to inhibit gastric acid secretion. It is commonly used in gastrointestinal conditions related to acid secretion, such as gastric ulcers and gastroesophageal reflux disease (GERD), in adults and children. Compared to other H<sub>2</su... | Moderate | 1 | [
[
[
1425,
24,
1559
]
],
[
[
1425,
6,
10215
],
[
10215,
45,
1559
]
],
[
[
1425,
23,
1247
],
[
1247,
62,
1559
]
],
[
[
1425,
24,
286
],
[
28... | [
[
[
"Cisapride",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Famotidine"
]
],
[
[
"Cisapride",
"{u} (Compound) binds {v} (Gene)",
"CYP2C19"
],
[
"CYP2C19",
"{u} (Gene) is bound by {v} (Compound)",... | Cisapride (Compound) binds CYP2C19 (Gene) and CYP2C19 (Gene) is bound by Famotidine (Compound)
Cisapride may cause a minor interaction that can limit clinical effects when taken with Sulfamethoxazole and Sulfamethoxazole may cause a minor interaction that can limit clinical effects when taken with Famotidine
Cisapride ... |
DB00712 | DB11703 | 1,274 | 405 | [
"DDInter763",
"DDInter9"
] | Flurbiprofen | Acalabrutinib | Flurbiprofen, a propionic acid derivative, is a nonsteroidal anti-inflammatory agent (NSAIA) with antipyretic and analgesic activity. Oral formulations of flurbiprofen may be used for the symptomatic treatment of rheumatoid arthritis, osteoarthritis and anklylosing spondylitis. Flurbiprofen may also be used topically p... | To date, acalabrutinib has been used in trials studying the treatment of B-All, myelofibrosis, ovarian cancer, multiple myeloma, and Hodgkin lymphoma, among others. As of October 31, 2017 the FDA approved Astra Zeneca's orally administered Calquence (acalabrutinib, capsules). This Bruton tyrosine kinase (BTK) inhibitor... | Major | 2 | [
[
[
1274,
37,
405
]
],
[
[
1274,
63,
139
],
[
139,
24,
405
]
],
[
[
1274,
24,
643
],
[
643,
24,
405
]
],
[
[
1274,
24,
1598
],
[
1598,
... | [
[
[
"Flurbiprofen",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v} and {u} may lead to a major life threatening interaction when taken with {v}",
"Acalabrutinib"
]
],
[
[
"Flurbiprofen",
"{u} may cause a moderate interaction tha... | Flurbiprofen may cause a moderate interaction that could exacerbate diseases when taken with Acalabrutinib and
Flurbiprofen may cause a moderate interaction that could exacerbate diseases when taken with Zidovudine and Zidovudine may cause a moderate interaction that could exacerbate diseases when taken with Acalabruti... |
DB06704 | DB06764 | 247 | 1,090 | [
"DDInter952",
"DDInter1787"
] | Iobenguane (I-131) | Tetryzoline (nasal) | 2-[(3-iodophenyl)methyl]guanidine is an organoiodine compound. | Tetryzoline is a member of imidazolines and a carboxamidine. It has a role as a sympathomimetic agent and a nasal decongestant. It is a conjugate base of a tetryzoline(1+). | Major | 2 | [
[
[
247,
25,
1090
]
],
[
[
247,
76,
1000
],
[
1000,
24,
1090
]
],
[
[
247,
64,
1290
],
[
1290,
24,
1090
]
],
[
[
247,
37,
41
],
[
41,
... | [
[
[
"Iobenguane",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tetryzoline"
]
],
[
[
"Iobenguane",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v} and {u} may lead to a major life threatening inter... | Iobenguane may lead to a major life threatening interaction when taken with Tetryzoline
Iobenguane may cause a moderate interaction that could exacerbate diseases when taken with Guanadrel and Iobenguane may lead to a major life threatening interaction when taken with Guanadrel and Guanadrel may cause a moderate intera... |
DB00773 | DB04865 | 896 | 4 | [
"DDInter702",
"DDInter1335"
] | Etoposide | Omacetaxine mepesuccinate | A semisynthetic derivative of podophyllotoxin that exhibits antitumor activity. Etoposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA. This complex induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent entry into the mitoti... | Omacetaxine mepesuccinate (formerly known as HHT or Homoharringtonine), is a cephalotaxine ester and protein synthesis inhibitor with established clinical activity as a single agent in hematological malignancies. Omacetaxine mepesuccinate is synthesized from cephalotaxine, which is an extract from the leaves of the pla... | Moderate | 1 | [
[
[
896,
24,
4
]
],
[
[
896,
7,
1830
],
[
1830,
46,
4
]
],
[
[
896,
18,
6461
],
[
6461,
46,
4
]
],
[
[
896,
34,
7720
],
[
7720,
46,
... | [
[
[
"Etoposide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Omacetaxine mepesuccinate"
]
],
[
[
"Etoposide",
"{u} (Compound) upregulates {v} (Gene)",
"BIRC3"
],
[
"BIRC3",
"{u} (Gene) is upregula... | Etoposide (Compound) upregulates BIRC3 (Gene) and BIRC3 (Gene) is upregulated by Omacetaxine mepesuccinate (Compound)
Etoposide (Compound) downregulates DDX10 (Gene) and DDX10 (Gene) is upregulated by Omacetaxine mepesuccinate (Compound)
Etoposide (Compound) binds PTGS2 (Gene) and Etoposide (Compound) upregulates PTGS2... |
DB09074 | DB12095 | 1,362 | 179 | [
"DDInter1327",
"DDInter1760"
] | Olaparib | Telotristat ethyl | Olaparib is a selective and potent inhibitor of poly (ADP-ribose) polymerase (PARP) enzymes, PARP1 and PARP2.[L41100, L40908, L43792] PARP inhibitors represent a novel class of anti-cancer therapy and they work by taking advantage of a defect in DNA repair in cancer cells with BRCA mutations and inducing cell death. Ol... | Telotristat ethyl is a prodrug of telotristat that was approved by the FDA in March 2017 as Xermelo. It was previously referred to as telotristat etiprate, the hippurate salt form; however, the FDA recommends the use of the name of the neutral form rather than that of the salt.[A252937, A252942] Currently, telotristat ... | Moderate | 1 | [
[
[
1362,
24,
179
]
],
[
[
1362,
63,
79
],
[
79,
24,
179
]
],
[
[
1362,
24,
214
],
[
214,
24,
179
]
],
[
[
1362,
64,
1593
],
[
1593,
... | [
[
[
"Olaparib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Telotristat ethyl"
]
],
[
[
"Olaparib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sorafenib"
],
[
... | Olaparib may cause a moderate interaction that could exacerbate diseases when taken with Sorafenib and Sorafenib may cause a moderate interaction that could exacerbate diseases when taken with Telotristat ethyl
Olaparib may cause a moderate interaction that could exacerbate diseases when taken with Fostamatinib and Fos... |
DB06210 | DB08903 | 72 | 996 | [
"DDInter631",
"DDInter170"
] | Eltrombopag | Bedaquiline | Eltrombopag is used to treat low blood platelet counts in adults with chronic immune (idiopathic) thrombocytopenia (ITP), when certain other medicines, or surgery to remove the spleen, have not worked well enough. ITP is a condition that may cause unusual bruising or bleeding due to an abnormally low number of platelet... | Bedaquiline is a bactericidal antimycobacterial drug belonging to the class of diarylquinoline. The quinolinic central heterocyclic nucleus with alcohol and amine side chains is responsible for bedaquiline-mediated antimycobacterial activity. Although it is closely related to fluoroquinolones, bedaquiline does not affe... | Moderate | 1 | [
[
[
72,
24,
996
]
],
[
[
72,
25,
350
],
[
350,
24,
996
]
],
[
[
72,
24,
1613
],
[
1613,
63,
996
]
],
[
[
72,
64,
491
],
[
491,
24,
... | [
[
[
"Eltrombopag",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bedaquiline"
]
],
[
[
"Eltrombopag",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Carfilzomib"
],
[
"Carfil... | Eltrombopag may lead to a major life threatening interaction when taken with Carfilzomib and Carfilzomib may cause a moderate interaction that could exacerbate diseases when taken with Bedaquiline
Eltrombopag may cause a moderate interaction that could exacerbate diseases when taken with Peginterferon beta-1a and Pegin... |
DB00277 | DB00532 | 1,031 | 208 | [
"DDInter1791",
"DDInter1152"
] | Theophylline | Mephenytoin | A methylxanthine derivative from tea with diuretic, smooth muscle relaxant, bronchial dilation, cardiac and central nervous system stimulant activities. Mechanistically, theophylline acts as a phosphodiesterase inhibitor, adenosine receptor blocker, and histone deacetylase activator. Theophylline is marketed under seve... | Mephenytoin is used for the treatment of refractory partial epilepsy. Mephenytoin is a solid. This compound belongs to the phenylhydantoins. These are heterocyclic aromatic compounds containing an imiazolidinedione moiety substituted by a phenyl group. Mephenytoin is known to target sodium channel protein type 5 subuni... | Moderate | 1 | [
[
[
1031,
24,
208
]
],
[
[
1031,
24,
660
],
[
660,
62,
208
]
],
[
[
1031,
23,
1096
],
[
1096,
62,
208
]
],
[
[
1031,
23,
1242
],
[
1242,
... | [
[
[
"Theophylline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mephenytoin"
]
],
[
[
"Theophylline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Esomeprazole"
],
... | Theophylline may cause a moderate interaction that could exacerbate diseases when taken with Esomeprazole and Esomeprazole may cause a minor interaction that can limit clinical effects when taken with Mephenytoin
Theophylline may cause a minor interaction that can limit clinical effects when taken with Mycophenolic aci... |
DB01240 | DB06779 | 885 | 365 | [
"DDInter657",
"DDInter470"
] | Epoprostenol | Dalteparin | A prostaglandin that is a powerful vasodilator and inhibits platelet aggregation. It is biosynthesized enzymatically from prostaglandin endoperoxides in human vascular tissue. The sodium salt has been also used to treat primary pulmonary hypertension. | Dalteparin, a low molecular weight heparin (LMWH) prepared by nitrous acid degradation of unfractionated heparin of porcine intestinal mucosa origin, is an anticoagulant. It is composed of strongly acidic sulphated polysaccharide chains with an average molecular weight of 5000 and about 90% of the material within the r... | Major | 2 | [
[
[
885,
25,
365
]
],
[
[
885,
23,
539
],
[
539,
62,
365
]
],
[
[
885,
63,
954
],
[
954,
24,
365
]
],
[
[
885,
24,
1427
],
[
1427,
6... | [
[
[
"Epoprostenol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dalteparin"
]
],
[
[
"Epoprostenol",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Capsicum"
],
[
"Capsicum",... | Epoprostenol may cause a minor interaction that can limit clinical effects when taken with Capsicum and Capsicum may cause a minor interaction that can limit clinical effects when taken with Dalteparin
Epoprostenol may cause a moderate interaction that could exacerbate diseases when taken with Quinapril and Quinapril m... |
DB00254 | DB01339 | 964 | 728 | [
"DDInter598",
"DDInter1922"
] | Doxycycline | Vecuronium | Doxycycline is a broad-spectrum antibiotic synthetically derived from [oxytetracycline]. It is a second-generation tetracycline that was first discovered in 1967. Second-generation tetracyclines exhibit lesser toxicity than first-generation tetracyclines. Doxycycline is used to treat a wide variety of gram-positive and... | Monoquaternary homolog of pancuronium. A non-depolarizing neuromuscular blocking agent with shorter duration of action than pancuronium. Its lack of significant cardiovascular effects and lack of dependence on good kidney function for elimination as well as its short duration of action and easy reversibility provide ad... | Moderate | 1 | [
[
[
964,
24,
728
]
],
[
[
964,
24,
1610
],
[
1610,
1,
728
]
],
[
[
964,
24,
1579
],
[
1579,
40,
728
]
],
[
[
964,
40,
1620
],
[
1620,
... | [
[
[
"Doxycycline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vecuronium"
]
],
[
[
"Doxycycline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rocuronium"
],
[
... | Doxycycline may cause a moderate interaction that could exacerbate diseases when taken with Rocuronium and Rocuronium (Compound) resembles Vecuronium (Compound)
Doxycycline may cause a moderate interaction that could exacerbate diseases when taken with Pancuronium and Pancuronium (Compound) resembles Vecuronium (Compou... |
DB00983 | DB01159 | 480 | 419 | [
"DDInter776",
"DDInter854"
] | Formoterol | Halothane | Formoterol is an inhaled beta<sub>2</sub>-agonist used in the management of COPD and asthma that was first approved for use in the United States in 2001. It acts on bronchial smooth muscle to dilate and relax airways, and is administered as a racemic mixture of its active (R;R)- and inactive (S;S)-enantiomers. A major ... | A nonflammable, halogenated, hydrocarbon anesthetic that provides relatively rapid induction with little or no excitement. Analgesia may not be adequate. nitrous oxide is often given concomitantly. Because halothane may not produce sufficient muscle relaxation, supplemental neuromuscular blocking agents may be required... | Moderate | 1 | [
[
[
480,
24,
419
]
],
[
[
480,
6,
12523
],
[
12523,
45,
419
]
],
[
[
480,
24,
774
],
[
774,
63,
419
]
],
[
[
480,
24,
1148
],
[
1148,
... | [
[
[
"Formoterol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Halothane"
]
],
[
[
"Formoterol",
"{u} (Compound) binds {v} (Gene)",
"CYP2D6"
],
[
"CYP2D6",
"{u} (Gene) is bound by {v} (Compound)",
... | Formoterol (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Halothane (Compound)
Formoterol may cause a moderate interaction that could exacerbate diseases when taken with Degarelix and Degarelix may cause a moderate interaction that could exacerbate diseases when taken with Halothane
Formoterol may cause a... |
DB00836 | DB12010 | 543 | 214 | [
"DDInter1088",
"DDInter785"
] | Loperamide | Fostamatinib | Loperamide is an anti-diarrheal agent that is available as various over-the-counter products for treating diarrhea. The drug was first synthesized in 1969 and used medically in 1976. It is a highly lipophilic synthetic phenylpiperidine opioid that is structurally similar to opiate receptor agonists such as [diphenoxyla... | Fostamatinib has been investigated for the treatment and basic science of Rheumatoid Arthritis and Immune Thrombocytopenic Purpura (ITP). It was approved on April 17, 2018, under the trade name Tavalisse for use in ITP [L2644, FDA Label]. Fostamatinib has also been granted orphan drug status by the FDA . Recently, fost... | Moderate | 1 | [
[
[
543,
24,
214
]
],
[
[
543,
63,
51
],
[
51,
24,
214
]
],
[
[
543,
24,
1005
],
[
1005,
24,
214
]
],
[
[
543,
25,
540
],
[
540,
24,... | [
[
[
"Loperamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fostamatinib"
]
],
[
[
"Loperamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Daunorubicin"
],
... | Loperamide may cause a moderate interaction that could exacerbate diseases when taken with Daunorubicin and Daunorubicin may cause a moderate interaction that could exacerbate diseases when taken with Fostamatinib
Loperamide may cause a moderate interaction that could exacerbate diseases when taken with Vardenafil and ... |
DB01176 | DB01192 | 537 | 560 | [
"DDInter453",
"DDInter1372"
] | Cyclizine | Oxymorphone | A histamine H1 antagonist given by mouth or parenterally for the control of postoperative and drug-induced vomiting and in motion sickness. (From Martindale, The Extra Pharmacopoeia, 30th ed, p935) | An opioid analgesic with actions and uses similar to those of morphine, apart from an absence of cough suppressant activity. It is used in the treatment of moderate to severe pain, including pain in obstetrics. It may also be used as an adjunct to anesthesia (From Martindale, The Extra Pharmacopoeia, 30th ed, p1092). O... | Moderate | 1 | [
[
[
537,
24,
560
]
],
[
[
537,
63,
828
],
[
828,
1,
560
]
],
[
[
537,
21,
28817
],
[
28817,
60,
560
]
],
[
[
537,
63,
1123
],
[
1123,
... | [
[
[
"Cyclizine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Oxymorphone"
]
],
[
[
"Cyclizine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Oxycodone"
],
[
... | Cyclizine may cause a moderate interaction that could exacerbate diseases when taken with Oxycodone and Oxycodone (Compound) resembles Oxymorphone (Compound)
Cyclizine (Compound) causes Vision blurred (Side Effect) and Vision blurred (Side Effect) is caused by Oxymorphone (Compound)
Cyclizine may cause a moderate inter... |
DB00188 | DB06292 | 168 | 549 | [
"DDInter222",
"DDInter474"
] | Bortezomib | Dapagliflozin | Bortezomib is a dipeptide boronic acid derivative and proteasome inhibitor used to treat multiple myeloma and mantle cell lymphoma. The 26S proteasome is a protein complex that degrades ubiquitinated proteins in the ubiquitin-proteasome pathway: reversible inhibition of the 26S proteasome, leading to cell cycle arrest ... | Dapagliflozin is a sodium-glucose cotransporter 2 (SGLT2) inhibitor, and it was the first SLGT2 inhibitor to be approved. indicated for managing diabetes mellitus type 2. When combined with diet and exercise in adults, dapagliflozin helps to improve glycemic control by inhibiting glucose reabsorption in the proximal tu... | Moderate | 1 | [
[
[
168,
24,
549
]
],
[
[
168,
24,
1344
],
[
1344,
40,
549
]
],
[
[
168,
6,
9842
],
[
9842,
45,
549
]
],
[
[
168,
21,
30077
],
[
30077,
... | [
[
[
"Bortezomib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dapagliflozin"
]
],
[
[
"Bortezomib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Canagliflozin"
],
... | Bortezomib may cause a moderate interaction that could exacerbate diseases when taken with Canagliflozin and Canagliflozin (Compound) resembles Dapagliflozin (Compound)
Bortezomib (Compound) binds CYP1A1 (Gene) and CYP1A1 (Gene) is bound by Dapagliflozin (Compound)
Bortezomib (Compound) causes Fluid overload (Side Effe... |
DB12141 | DB12267 | 971 | 1,476 | [
"DDInter817",
"DDInter233"
] | Gilteritinib | Brigatinib | Gilteritinib, also known as ASP2215, is a small molecule part of the FLT3 tyrosine kinase inhibitors that presented a greater selectivity and potency when compared with other agents from this group. It is a pyrazinecarboxamide derivative that showed high selectivity to FLT3 preventing the c-Kit -driven myelosuppression... | Brigatinib, originally named AP26113, is a reversible dual inhibitor of anaplastic lymphoma kinase (ALK) and epidermal growth factor receptor (EGFR). It presents selectivity against the mutant forms of EGFR compared to the wild-type. It also exhibits selectivity against 9 different Crizotinib-resistant mutants of the E... | Moderate | 1 | [
[
[
971,
24,
1476
]
],
[
[
971,
63,
1612
],
[
1612,
23,
1476
]
],
[
[
971,
62,
1135
],
[
1135,
23,
1476
]
],
[
[
971,
63,
629
],
[
629,
... | [
[
[
"Gilteritinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brigatinib"
]
],
[
[
"Gilteritinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fostemsavir"
],
... | Gilteritinib may cause a moderate interaction that could exacerbate diseases when taken with Fostemsavir and Fostemsavir may cause a minor interaction that can limit clinical effects when taken with Brigatinib
Gilteritinib may cause a minor interaction that can limit clinical effects when taken with Naloxegol and Nalox... |
DB00295 | DB00678 | 475 | 240 | [
"DDInter1244",
"DDInter1095"
] | Morphine | Losartan | Morphine, the main alkaloid of opium, was first obtained from poppy seeds in 1805. It is a potent analgesic, though its use is limited due to tolerance, withdrawal, and the risk of abuse. Morphine is still routinely used today, though there are a number of semi-synthetic opioids of varying strength such as [codeine], [... | Losartan is an angiotensin II receptor blocker (ARB) used to treat hypertension. Angiotensin-converting enzyme (ACE) inhibitors are used for a similar indication but are associated with a cough. When patients with ACE inhibitor associated coughs are switched to ARBs like losartan, they have an incidence of cough simila... | Moderate | 1 | [
[
[
475,
24,
240
]
],
[
[
475,
24,
1414
],
[
1414,
1,
240
]
],
[
[
475,
63,
217
],
[
217,
1,
240
]
],
[
[
475,
24,
911
],
[
911,
40,... | [
[
[
"Morphine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Losartan"
]
],
[
[
"Morphine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Eprosartan"
],
[
"E... | Morphine may cause a moderate interaction that could exacerbate diseases when taken with Eprosartan and Eprosartan (Compound) resembles Losartan (Compound)
Morphine may cause a moderate interaction that could exacerbate diseases when taken with Olmesartan and Olmesartan (Compound) resembles Losartan (Compound)
Morphine... |
DB00358 | DB01224 | 1,010 | 623 | [
"DDInter1140",
"DDInter1553"
] | Mefloquine | Quetiapine | Malaria is a protozoan disease that places an enormous burden on human health in endemic areas around the world. The 2020 World Health Organization malaria report indicates a 60% decrease in the global malaria fatality rate between 2000 to 2019. Despite this, malaria remains a significant cause of morbidity and mortali... | Initially approved by the FDA in 1997, quetiapine is a second-generation atypical antipsychotic used in schizophrenia, major depression, and bipolar disorder. Quetiapine demonstrates a high level of therapeutic efficacy and low risk of adverse effects during long-term treatment. It is well-tolerated and a suitable opti... | Moderate | 1 | [
[
[
1010,
24,
623
]
],
[
[
1010,
24,
827
],
[
827,
1,
623
]
],
[
[
1010,
25,
695
],
[
695,
1,
623
]
],
[
[
1010,
63,
867
],
[
867,
1... | [
[
[
"Mefloquine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Quetiapine"
]
],
[
[
"Mefloquine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trazodone"
],
[
... | Mefloquine may cause a moderate interaction that could exacerbate diseases when taken with Trazodone and Trazodone (Compound) resembles Quetiapine (Compound)
Mefloquine may lead to a major life threatening interaction when taken with Clozapine and Clozapine (Compound) resembles Quetiapine (Compound)
Mefloquine may caus... |
DB00431 | DB01598 | 1,503 | 483 | [
"DDInter1072",
"DDInter911"
] | Lindane | Imipenem | An organochlorine insecticide that has been used as a pediculicide and a scabicide. Lindane has been banned in California, United Kingdom, Australia, and many western countries due to concerns about neurotoxicity and adverse effects on the environment. In Canada, Lindane is not recommmended as a first-line therapy due ... | Imipenem is a semisynthetic thienamycin that has a wide spectrum of antibacterial activity against gram-negative and gram-positive aerobic and anaerobic bacteria, including many multiresistant strains.[label] It is stable to many beta-lactamases. Similar compounds include [meropenem], known for having greater activity ... | Moderate | 1 | [
[
[
1503,
24,
483
]
],
[
[
1503,
63,
1031
],
[
1031,
24,
483
]
],
[
[
1503,
25,
497
],
[
497,
25,
483
]
],
[
[
1503,
63,
1031
],
[
1031,
... | [
[
[
"Lindane",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Imipenem"
]
],
[
[
"Lindane",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Theophylline"
],
[
"T... | Lindane may cause a moderate interaction that could exacerbate diseases when taken with Theophylline and Theophylline may cause a moderate interaction that could exacerbate diseases when taken with Imipenem
Lindane may lead to a major life threatening interaction when taken with Iohexol and Iohexol may lead to a major ... |
DB12001 | DB15093 | 564 | 1,654 | [
"DDInter7",
"DDInter1698"
] | Abemaciclib | Somapacitan | Abemaciclib is an antitumor agent and dual inhibitor of cyclin-dependent kinases 4 (CDK4) and 6 (CDK6) that are involved in the cell cycle and promotion of cancer cell growth in case of unregulated activity. On September 28, 2017, FDA granted approval of abemaciclib treatment under the market name Verzenio for the trea... | Somapacitan, also known as NNC0195-0092, is a growth hormone analog indicated to treat adults with growth hormone deficiency.[A219126,L15661] This human growth hormone analog differs by the creation of an albumin binding site, and prolonging the effect so that it requires weekly dosing rather than daily. Somapacitan wa... | Moderate | 1 | [
[
[
564,
24,
1654
]
],
[
[
564,
63,
351
],
[
351,
24,
1654
]
],
[
[
564,
24,
159
],
[
159,
24,
1654
]
],
[
[
564,
25,
676
],
[
676,
... | [
[
[
"Abemaciclib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Somapacitan"
]
],
[
[
"Abemaciclib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ribociclib"
],
[... | Abemaciclib may cause a moderate interaction that could exacerbate diseases when taken with Ribociclib and Ribociclib may cause a moderate interaction that could exacerbate diseases when taken with Somapacitan
Abemaciclib may cause a moderate interaction that could exacerbate diseases when taken with Larotrectinib and ... |
DB00330 | DB01098 | 238 | 14 | [
"DDInter689",
"DDInter1622"
] | Ethambutol | Rosuvastatin | Ethambutol is a bacteriostatic agent indicated alongside medications such as [isoniazid], [rifampin], and [pyrazinamide] in the treatment of pulmonary tuberculosis. Ethambutol was first described in the literature in 1961. It was developed out of a need for therapies active against isoniazid resistant strains of _Mycob... | Rosuvastatin, also known as the brand name product Crestor, is a lipid-lowering drug that belongs to the statin class of medications, which are used to lower the risk of cardiovascular disease and manage elevated lipid levels by inhibiting the endogenous production of cholesterol in the liver. More specifically, statin... | Moderate | 1 | [
[
[
238,
24,
14
]
],
[
[
238,
21,
28900
],
[
28900,
60,
14
]
],
[
[
238,
63,
305
],
[
305,
24,
14
]
],
[
[
238,
24,
1487
],
[
1487,
... | [
[
[
"Ethambutol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rosuvastatin"
]
],
[
[
"Ethambutol",
"{u} (Compound) causes {v} (Side Effect)",
"Abdominal pain"
],
[
"Abdominal pain",
"{u} (Side Eff... | Ethambutol (Compound) causes Abdominal pain (Side Effect) and Abdominal pain (Side Effect) is caused by Rosuvastatin (Compound)
Ethambutol may cause a moderate interaction that could exacerbate diseases when taken with Asparaginase Escherichia coli and Asparaginase Escherichia coli may cause a moderate interaction that... |
DB00055 | DB05773 | 834 | 1,047 | [
"DDInter605",
"DDInter1848"
] | Drotrecogin alfa | Trastuzumab emtansine | Drotrecogin alfa is activated human protein C that is synthesized by recombinant DNA technology. It is a glycoprotein of approximately 55 kilodalton molecular weight, consisting of a heavy chain and a light chain linked by a disulfide bond. Drotrecogin alfa was withdrawn from the market after a major study indicated th... | Trastuzumab emtansine, formerly called Trastuzumab-DM1 (T-DM1) is a first-in-class HER2 antibody drug conjugate (ADC) comprised of Genentech's trastuzumab antibody linked to ImmunoGen's cell-killing agent, DM1. T-DM1 combines two strategies-- anti-HER2 activity and targeted intracellular delivery of the potent anti-mic... | Major | 2 | [
[
[
834,
25,
1047
]
],
[
[
834,
25,
848
],
[
848,
24,
1047
]
],
[
[
834,
24,
643
],
[
643,
63,
1047
]
],
[
[
834,
24,
1230
],
[
1230,
... | [
[
[
"Drotrecogin alfa",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Trastuzumab emtansine"
]
],
[
[
"Drotrecogin alfa",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ibuprofen"
],
[
"Ibu... | Drotrecogin alfa may lead to a major life threatening interaction when taken with Ibuprofen and Ibuprofen may cause a moderate interaction that could exacerbate diseases when taken with Trastuzumab emtansine
Drotrecogin alfa may cause a moderate interaction that could exacerbate diseases when taken with Desvenlafaxine ... |
DB00176 | DB00278 | 529 | 291 | [
"DDInter770",
"DDInter117"
] | Fluvoxamine | Argatroban | Fluvoxamine is an antidepressant which functions pharmacologically as a selective serotonin reuptake inhibitor. Though it is in the same class as other SSRI drugs, it is most often used to treat obsessive-compulsive disorder. Fluvoxamine has been in use in clinical practice since 1983 and has a clinical trial database ... | Argatroban is a direct, selective thrombin inhibitor. The American College of Cardiologists (ACC) recommend using bivalirudin or argatroban in patients who have had, or at risk for, heparin induced thrombocytopenia (HIT) and are undergoing percutaneous coronary intervention. Argatroban is a non-heparin anticoagulant sh... | Moderate | 1 | [
[
[
529,
24,
291
]
],
[
[
529,
6,
8374
],
[
8374,
45,
291
]
],
[
[
529,
21,
28931
],
[
28931,
60,
291
]
],
[
[
529,
25,
121
],
[
121,
... | [
[
[
"Fluvoxamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Argatroban"
]
],
[
[
"Fluvoxamine",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)... | Fluvoxamine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Argatroban (Compound)
Fluvoxamine (Compound) causes Haemorrhage (Side Effect) and Haemorrhage (Side Effect) is caused by Argatroban (Compound)
Fluvoxamine may lead to a major life threatening interaction when taken with Fenfluramine and Fenflurami... |
DB06016 | DB08820 | 1,508 | 1,478 | [
"DDInter300",
"DDInter997"
] | Cariprazine | Ivacaftor | Cariprazine is an atypical antipsychotic agent and a piperazine derivative that was first developed in Hungary. It works as a partial agonist at central dopamine D2, dopamine D3, and serotonin 5-HT<sub>1A</sub> receptors and as an antagonist at serotonin 5-HT<sub>2A</sub> receptors. Cariprazine has been investigated in... | Ivacaftor (also known as Kalydeco or VX-770) is a drug used for the management of Cystic Fibrosis (CF). It is manufactured and distributed by Vertex Pharmaceuticals. It was approved by the Food and Drug Administration on January 31, 2012, and by Health Canada in late 2012. Ivacaftor is administered as a monotherapy and... | Moderate | 1 | [
[
[
1508,
24,
1478
]
],
[
[
1508,
63,
1411
],
[
1411,
24,
1478
]
],
[
[
1508,
24,
1040
],
[
1040,
63,
1478
]
],
[
[
1508,
24,
578
],
[
578... | [
[
[
"Cariprazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ivacaftor"
]
],
[
[
"Cariprazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tolbutamide"
],
[
... | Cariprazine may cause a moderate interaction that could exacerbate diseases when taken with Tolbutamide and Tolbutamide may cause a moderate interaction that could exacerbate diseases when taken with Ivacaftor
Cariprazine may cause a moderate interaction that could exacerbate diseases when taken with Dabrafenib and Dab... |
DB00284 | DB00880 | 1,647 | 359 | [
"DDInter11",
"DDInter360"
] | Acarbose | Chlorothiazide | Acarbose is a complex oligosaccharide that acts as an inhibitor of several enzymes responsible for the breakdown of complex carbohydrates in the intestines. It inhibits both pancreatic alpha-amylase and membrane-bound alpha-glucosidases - including intestinal glucoamylase, sucrase, maltase, and isomaltase - which are r... | A thiazide diuretic with actions and uses similar to those of hydrochlorothiazide. (From Martindale, The Extra Pharmacopoeia, 30th ed, p812) | Moderate | 1 | [
[
[
1647,
24,
359
]
],
[
[
1647,
24,
1577
],
[
1577,
1,
359
]
],
[
[
1647,
21,
28784
],
[
28784,
60,
359
]
],
[
[
1647,
23,
126
],
[
126,
... | [
[
[
"Acarbose",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Chlorothiazide"
]
],
[
[
"Acarbose",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hydroflumethiazide"
],
... | Acarbose may cause a moderate interaction that could exacerbate diseases when taken with Hydroflumethiazide and Hydroflumethiazide (Compound) resembles Chlorothiazide (Compound)
Acarbose (Compound) causes Thrombocytopenia (Side Effect) and Thrombocytopenia (Side Effect) is caused by Chlorothiazide (Compound)
Acarbose m... |
DB00502 | DB00526 | 1,300 | 1,555 | [
"DDInter853",
"DDInter1355"
] | Haloperidol | Oxaliplatin | Haloperidol is a high potency first-generation (typical) antipsychotic and one of the most frequently used antipsychotic medications used worldwide. While haloperidol has demonstrated pharmacologic activity at a number of receptors in the brain, it exerts its antipsychotic effect through its strong antagonism of the do... | Oxaliplatin is a platinum-based chemotherapy drug in the same family as cisplatin and carboplatin. Compared to cisplatin the two amine groups are replaced by diamino cyclohexane (DACH) group to provide a greater antitumor effect. However, this leads to poorer water solubility, which was compensated by the addition of t... | Major | 2 | [
[
[
1300,
25,
1555
]
],
[
[
1300,
6,
7950
],
[
7950,
45,
1555
]
],
[
[
1300,
64,
79
],
[
79,
24,
1555
]
],
[
[
1300,
25,
1213
],
[
1213,
... | [
[
[
"Haloperidol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Oxaliplatin"
]
],
[
[
"Haloperidol",
"{u} (Compound) binds {v} (Gene)",
"CYP1A2"
],
[
"CYP1A2",
"{u} (Gene) is bound by {v} (Compound)",
"Oxal... | Haloperidol (Compound) binds CYP1A2 (Gene) and CYP1A2 (Gene) is bound by Oxaliplatin (Compound)
Haloperidol may lead to a major life threatening interaction when taken with Sorafenib and Sorafenib may cause a moderate interaction that could exacerbate diseases when taken with Oxaliplatin
Haloperidol may lead to a major... |
DB00674 | DB09472 | 1,516 | 1,383 | [
"DDInter802",
"DDInter1693"
] | Galantamine | Sodium sulfate | Galantamine is a tertiary alkaloid and reversible, competitive inhibitor of the acetylcholinesterase (AChE) enzyme, which is a widely studied therapeutic target used in the treatment of Alzheimer's disease. First characterized in the early 1950s, galantamine is a tertiary alkaloid that was extracted from botanical sour... | Sodium Sulfate Anhydrous is the anhydrous, sodium salt form of sulfuric acid. Sodium sulfate anhydrous disassociates in water to provide sodium ions and sulfate ions. Sodium ion is the principal cation of the extracellular fluid and plays a large part in the therapy of fluid and electrolyte disturbances. Sodium sulfate... | Moderate | 1 | [
[
[
1516,
24,
1383
]
],
[
[
1516,
24,
678
],
[
678,
24,
1383
]
],
[
[
1516,
63,
521
],
[
521,
24,
1383
]
],
[
[
1516,
24,
971
],
[
971,
... | [
[
[
"Galantamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sodium sulfate"
]
],
[
[
"Galantamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Oxamniquine"
],
... | Galantamine may cause a moderate interaction that could exacerbate diseases when taken with Oxamniquine and Oxamniquine may cause a moderate interaction that could exacerbate diseases when taken with Sodium sulfate
Galantamine may cause a moderate interaction that could exacerbate diseases when taken with Goserelin and... |
DB01045 | DB01229 | 463 | 973 | [
"DDInter1590",
"DDInter1378"
] | Rifampicin | Paclitaxel (protein-bound) | A semisynthetic antibiotic produced from Streptomyces mediterranei. It has a broad antibacterial spectrum, including activity against several forms of Mycobacterium. In susceptible organisms it inhibits DNA-dependent RNA polymerase activity by forming a stable complex with the enzyme. It thus suppresses the initiation ... | Paclitaxel can cause developmental toxicity, female reproductive toxicity and male reproductive toxicity according to state or federal government labeling requirements. | Moderate | 1 | [
[
[
463,
24,
973
]
],
[
[
463,
24,
310
],
[
310,
63,
973
]
],
[
[
463,
6,
7524
],
[
7524,
45,
973
]
],
[
[
463,
25,
214
],
[
214,
63... | [
[
[
"Rifampicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Paclitaxel"
]
],
[
[
"Rifampicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cabazitaxel"
],
[
... | Rifampicin may cause a moderate interaction that could exacerbate diseases when taken with Paclitaxel
Rifampicin may cause a moderate interaction that could exacerbate diseases when taken with Cabazitaxel and Cabazitaxel may cause a moderate interaction that could exacerbate diseases when taken with Paclitaxel
Rifampic... |
DB01210 | DB01249 | 668 | 258 | [
"DDInter1050",
"DDInter958"
] | Levobunolol (ophthalmic) | Iodixanol | Levobunolol is a cyclic ketone that is 3,4-dihydronaphthalen-1-one substituted at position 5 by a 3-(tert-butylamino)-2-hydroxypropoxy group (the S-enantiomer). A non-selective beta-adrenergic antagonist used (as its hydrochloride salt) for treatment of glaucoma. It has a role as an antiglaucoma drug and a beta-adrener... | Iodixanol is a nonionic hydrophilic compound commonly used as a contrast agent during coronary angiography, particularly in individuals with renal dysfunction, as it is believed to be less toxic to the kidneys than most other intravascular contrast agents. | Moderate | 1 | [
[
[
668,
24,
258
]
],
[
[
668,
24,
497
],
[
497,
1,
258
]
],
[
[
668,
21,
28644
],
[
28644,
60,
258
]
],
[
[
668,
40,
461
],
[
461,
... | [
[
[
"Levobunolol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Iodixanol"
]
],
[
[
"Levobunolol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Iohexol"
],
[
... | Levobunolol may cause a moderate interaction that could exacerbate diseases when taken with Iodixanol
Levobunolol may cause a moderate interaction that could exacerbate diseases when taken with Iohexol and Iohexol (Compound) resembles Iodixanol (Compound)
Levobunolol (Compound) causes Syncope (Side Effect) and Syncope ... |
DB00211 | DB06764 | 1,290 | 1,090 | [
"DDInter1213",
"DDInter1787"
] | Midodrine | Tetryzoline (nasal) | An ethanolamine derivative that is an adrenergic alpha agonist. It is used as a vasoconstrictor agent in the treatment of hypotension. | Tetryzoline is a member of imidazolines and a carboxamidine. It has a role as a sympathomimetic agent and a nasal decongestant. It is a conjugate base of a tetryzoline(1+). | Moderate | 1 | [
[
[
1290,
24,
1090
]
],
[
[
1290,
24,
144
],
[
144,
63,
1090
]
],
[
[
1290,
24,
688
],
[
688,
24,
1090
]
],
[
[
1290,
25,
247
],
[
247,
... | [
[
[
"Midodrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tetryzoline"
]
],
[
[
"Midodrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Olodaterol"
],
[
... | Midodrine may cause a moderate interaction that could exacerbate diseases when taken with Tetryzoline
Midodrine may cause a moderate interaction that could exacerbate diseases when taken with Olodaterol and Olodaterol may cause a moderate interaction that could exacerbate diseases when taken with Tetryzoline
Midodrine ... |
DB01101 | DB05679 | 60 | 1,683 | [
"DDInter285",
"DDInter1907"
] | Capecitabine | Ustekinumab | Capecitabine is an orally-administered chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. Capecitabine is a prodrug, that is enzymatically converted to fluorouracil (antimetabolite) in the tumor, where it inhibits DNA synthesis and slows growth of tumor tissue. | Ustekinumab is a human immunoglobulin (Ig) G1 kappa monoclonal antibody directed against interleukin(IL)-12 and IL-23, which are cytokines that are involved in immune and inflammatory responses. It was generated via recombinant human IL-12 immunization of human Ig (hu-Ig) transgenic mice. It is a targeted biologic dise... | Moderate | 1 | [
[
[
60,
24,
1683
]
],
[
[
60,
63,
1461
],
[
1461,
23,
1683
]
],
[
[
60,
24,
1362
],
[
1362,
63,
1683
]
],
[
[
60,
63,
1307
],
[
1307,
... | [
[
[
"Capecitabine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ustekinumab"
]
],
[
[
"Capecitabine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vitamin E"
],
... | Capecitabine may cause a moderate interaction that could exacerbate diseases when taken with Vitamin E and Vitamin E may cause a minor interaction that can limit clinical effects when taken with Ustekinumab
Capecitabine may cause a moderate interaction that could exacerbate diseases when taken with Olaparib and Olapari... |
DB00274 | DB09268 | 277 | 1,662 | [
"DDInter320",
"DDInter1464"
] | Cefmetazole | Picosulfuric acid | A semisynthetic cephamycin antibiotic with a broad spectrum of activity against both gram-positive and gram-negative microorganisms. It has a high rate of efficacy in many types of infection and to date no severe side effects have been noted. | Picosulfuric acid is found in laxative products. Sodium picosulfate is a used to treat constipation or induce colon cleansing to prepare the large bowels before colonoscopy or surgery. The combination product containing sodium picosulfate and magnesium citrate was introduced to the Canadian market in 2005 and has been ... | Moderate | 1 | [
[
[
277,
24,
1662
]
],
[
[
277,
24,
597
],
[
597,
24,
1662
]
],
[
[
277,
1,
1558
],
[
1558,
24,
1662
]
],
[
[
277,
24,
597
],
[
597,
... | [
[
[
"Cefmetazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Picosulfuric acid"
]
],
[
[
"Cefmetazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Chloramphenicol"
... | Cefmetazole may cause a moderate interaction that could exacerbate diseases when taken with Chloramphenicol and Chloramphenicol may cause a moderate interaction that could exacerbate diseases when taken with Picosulfuric acid
Cefmetazole (Compound) resembles Cefoxitin (Compound) and Cefoxitin may cause a moderate inter... |
DB00039 | DB00078 | 1,253 | 1,172 | [
"DDInter1380",
"DDInter898"
] | Palifermin | Ibritumomab tiuxetan | Palifermin is a recombinant human keratinocyte growth factor (KGF). It is 140 residues long, and is produced using E. coli. Palifermin was granted FDA approval on 15 December 2004. | Indium or yttrium conjugated murine IgG1 kappa monoclonal antibody directed against the CD20 antigen, which is found on the surface of normal and malignant B lymphocytes. Ibritumomab is produced in Chinese hamster ovary cells and is composed of two murine gamma 1 heavy chains of 445 amino acids each and two kappa light... | Moderate | 1 | [
[
[
1253,
24,
1172
]
],
[
[
1253,
24,
869
],
[
869,
63,
1172
]
],
[
[
1253,
24,
397
],
[
397,
64,
1172
]
],
[
[
1253,
24,
869
],
[
869,
... | [
[
[
"Palifermin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ibritumomab tiuxetan"
]
],
[
[
"Palifermin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Topotecan"
],... | Palifermin may cause a moderate interaction that could exacerbate diseases when taken with Topotecan and Topotecan may cause a moderate interaction that could exacerbate diseases when taken with Ibritumomab tiuxetan
Palifermin may cause a moderate interaction that could exacerbate diseases when taken with Plicamycin an... |
DB08875 | DB11691 | 1,618 | 1,499 | [
"DDInter262",
"DDInter1258"
] | Cabozantinib | Naldemedine | Cabozantinib was first approved in 2012 and is a non-specific tyrosine kinase inhibitor. It was initially approved in the US under the brand name Cometriq, which is indicated for the treatment of metastatic medullary thyroid cancer. In 2016, a capsule formulation (Cabometyx) was approved for the treatment of advanced r... | Naldemedine is an opioid receptor antagonist [FDA Label]. It is a modified form of to which a side chain has been added to increase molecular weight and polar surface area resulting in restricted transport across the blood brain barrier. Naldemedine was approved in 2017 in both the US and Japan for the treatment of Opi... | Moderate | 1 | [
[
[
1618,
24,
1499
]
],
[
[
1618,
63,
307
],
[
307,
23,
1499
]
],
[
[
1618,
64,
932
],
[
932,
24,
1499
]
],
[
[
1618,
63,
723
],
[
723,
... | [
[
[
"Cabozantinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Naldemedine"
]
],
[
[
"Cabozantinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Modafinil"
],
... | Cabozantinib may cause a moderate interaction that could exacerbate diseases when taken with Modafinil and Modafinil may cause a minor interaction that can limit clinical effects when taken with Naldemedine
Cabozantinib may lead to a major life threatening interaction when taken with Mifepristone and Mifepristone may c... |
DB00563 | DB05015 | 663 | 1,077 | [
"DDInter1174",
"DDInter174"
] | Methotrexate | Belinostat | Methotrexate is a folate derivative that inhibits several enzymes responsible for nucleotide synthesis. This inhibition leads to suppression of inflammation as well as prevention of cell division. Because of these effects, methotrexate is often used to treat inflammation caused by arthritis or to control cell division ... | Belinostat is a novel agent that inhibits the enzyme histone deacetylase (HDAC) with a sulfonamide-hydroxamide structure. It was developed as an orphan drug to target hematological malignancies and solid tumors by TopoTarget. The safety and efficacy of belinostat is currently being evaluated for use in combination with... | Moderate | 1 | [
[
[
663,
24,
1077
]
],
[
[
663,
63,
1253
],
[
1253,
24,
1077
]
],
[
[
663,
24,
1136
],
[
1136,
63,
1077
]
],
[
[
663,
24,
869
],
[
869,
... | [
[
[
"Methotrexate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Belinostat"
]
],
[
[
"Methotrexate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Palifermin"
],
... | Methotrexate may cause a moderate interaction that could exacerbate diseases when taken with Palifermin and Palifermin may cause a moderate interaction that could exacerbate diseases when taken with Belinostat
Methotrexate may cause a moderate interaction that could exacerbate diseases when taken with Denosumab and Den... |
DB00502 | DB00681 | 1,300 | 1,287 | [
"DDInter853",
"DDInter85"
] | Haloperidol | Amphotericin B | Haloperidol is a high potency first-generation (typical) antipsychotic and one of the most frequently used antipsychotic medications used worldwide. While haloperidol has demonstrated pharmacologic activity at a number of receptors in the brain, it exerts its antipsychotic effect through its strong antagonism of the do... | Amphotericin B shows a high order of in vitro activity against many species of fungi. Histoplasma capsulatum, Coccidioides immitis, Candida species, Blastomyces dermatitidis, Rhodotorula, Cryptococcus neoformans, Sporothrix schenckii, Mucor mucedo, and Aspergillus fumigatus are all inhibited by concentrations of amphot... | Moderate | 1 | [
[
[
1300,
24,
1287
]
],
[
[
1300,
21,
28841
],
[
28841,
60,
1287
]
],
[
[
1300,
64,
600
],
[
600,
23,
1287
]
],
[
[
1300,
23,
663
],
[
663... | [
[
[
"Haloperidol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Amphotericin B"
]
],
[
[
"Haloperidol",
"{u} (Compound) causes {v} (Side Effect)",
"Bronchospasm"
],
[
"Bronchospasm",
"{u} (Side Eff... | Haloperidol (Compound) causes Bronchospasm (Side Effect) and Bronchospasm (Side Effect) is caused by Amphotericin B (Compound)
Haloperidol may lead to a major life threatening interaction when taken with Fluconazole and Fluconazole may cause a minor interaction that can limit clinical effects when taken with Amphoteric... |
DB00012 | DB00881 | 1,535 | 954 | [
"DDInter479",
"DDInter1554"
] | Darbepoetin alfa | Quinapril | Human erythropoietin with 2 aa substitutions to enhance glycosylation (5 N-linked chains), 165 residues (MW=37 kD). Produced in Chinese hamster ovary (CHO) cells by recombinant DNA technology. | Quinapril is the ethyl ester prodrug of the non-sulfhydryl angiotensin converting enzyme inhibitor quinaprilat.[L8420,L8423] It is used to treat hypertension and heart failure.[L8420,L8423] ACE inhibitors are commonly used as a first line therapy in the treatment of hypertension, along with thiazide diuretics or beta b... | Minor | 0 | [
[
[
1535,
23,
954
]
],
[
[
1535,
23,
1638
],
[
1638,
1,
954
]
],
[
[
1535,
23,
1638
],
[
1638,
1,
610
],
[
610,
1,
954
]
],
[
[
1535,
... | [
[
[
"Darbepoetin alfa",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Quinapril"
]
],
[
[
"Darbepoetin alfa",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Trandolapril"
],... | Darbepoetin alfa may cause a minor interaction that can limit clinical effects when taken with Trandolapril and Trandolapril (Compound) resembles Quinapril (Compound)
Darbepoetin alfa may cause a minor interaction that can limit clinical effects when taken with Trandolapril and Trandolapril (Compound) resembles Enalapr... |
DB01128 | DB09330 | 918 | 985 | [
"DDInter204",
"DDInter1352"
] | Bicalutamide | Osimertinib | Bicalutamide is an oral non-steroidal anti-androgen for prostate cancer. It is comprised of a racemic mixture that is a 50:50 composition of the (R)-bicalutamide and (S)-bicalutamide enantionmers. Bicalutamide binds to the androgen receptor. | Osimertinib is an oral, third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) drug developed by AstraZeneca Pharmaceuticals.[A7926,L43453] Its use is indicated for the treatment of metastatic non-small cell lung cancer (NSCLC) in cases where tumour EGFR expression is positive for the ... | Major | 2 | [
[
[
918,
25,
985
]
],
[
[
918,
62,
1247
],
[
1247,
23,
985
]
],
[
[
918,
24,
1478
],
[
1478,
24,
985
]
],
[
[
918,
63,
480
],
[
480,
... | [
[
[
"Bicalutamide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Osimertinib"
]
],
[
[
"Bicalutamide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Sulfamethoxazole"
],
[
"S... | Bicalutamide may cause a minor interaction that can limit clinical effects when taken with Sulfamethoxazole and Sulfamethoxazole may cause a minor interaction that can limit clinical effects when taken with Osimertinib
Bicalutamide may cause a moderate interaction that could exacerbate diseases when taken with Ivacafto... |
DB00222 | DB01234 | 245 | 1,220 | [
"DDInter825",
"DDInter513"
] | Glimepiride | Dexamethasone | First introduced in 1995, glimepiride is a member of the second-generation sulfonylurea (SU) drug class used for the management of type 2 diabetes mellitus (T2DM) to improve glycemic control. Type 2 diabetes is a metabolic disorder with increasing prevalences worldwide; it is characterized by insulin resistance in acco... | Dexamethasone, or MK-125, is a corticosteroid fluorinated at position 9 used to treat endocrine, rheumatic, collagen, dermatologic, allergic, ophthalmic, gastrointestinal, respiratory, hematologic, neoplastic, edematous, and other conditions. Developed in 1957, it is structurally similar to other corticosteroids like [... | Moderate | 1 | [
[
[
245,
24,
1220
]
],
[
[
245,
24,
870
],
[
870,
1,
1220
]
],
[
[
245,
24,
175
],
[
175,
40,
1220
]
],
[
[
245,
23,
1103
],
[
1103,
... | [
[
[
"Glimepiride",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dexamethasone"
]
],
[
[
"Glimepiride",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fludrocortisone"
]... | Glimepiride may cause a moderate interaction that could exacerbate diseases when taken with Fludrocortisone and Fludrocortisone (Compound) resembles Dexamethasone (Compound)
Glimepiride may cause a moderate interaction that could exacerbate diseases when taken with Triamcinolone and Triamcinolone (Compound) resembles D... |
DB00987 | DB05679 | 1,224 | 1,683 | [
"DDInter460",
"DDInter1907"
] | Cytarabine | Ustekinumab | A pyrimidine nucleoside analog that is used mainly in the treatment of leukemia, especially acute non-lymphoblastic leukemia. Cytarabine is an antimetabolite antineoplastic agent that inhibits the synthesis of DNA. Its actions are specific for the S phase of the cell cycle. It also has antiviral and immunosuppressant p... | Ustekinumab is a human immunoglobulin (Ig) G1 kappa monoclonal antibody directed against interleukin(IL)-12 and IL-23, which are cytokines that are involved in immune and inflammatory responses. It was generated via recombinant human IL-12 immunization of human Ig (hu-Ig) transgenic mice. It is a targeted biologic dise... | Moderate | 1 | [
[
[
1224,
24,
1683
]
],
[
[
1224,
63,
1461
],
[
1461,
23,
1683
]
],
[
[
1224,
24,
1362
],
[
1362,
63,
1683
]
],
[
[
1224,
63,
305
],
[
305... | [
[
[
"Cytarabine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ustekinumab"
]
],
[
[
"Cytarabine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vitamin E"
],
[
... | Cytarabine may cause a moderate interaction that could exacerbate diseases when taken with Vitamin E and Vitamin E may cause a minor interaction that can limit clinical effects when taken with Ustekinumab
Cytarabine may cause a moderate interaction that could exacerbate diseases when taken with Olaparib and Olaparib ma... |
DB06290 | DB12500 | 1,449 | 283 | [
"DDInter1673",
"DDInter714"
] | Simeprevir | Fedratinib | Simeprevir is a hepatitis C virus (HCV) NS3/4A protease inhibitor indicated in patient's with HCV genotype 1 for the treatment of chronic hepatitis C virus (HCV) infection. HCV is a single-stranded RNA virus that is categorized into nine distinct genotypes, with genotype 1 being the most common in the United States, an... | Fedratinib, also known as SAR302503 and TG101348, is a tyrosine kinase inhibitor used to treat intermediate-2 and high risk primary and secondary myelofibrosis.[A183176,L8090] It is an anilinopyrimidine derivative. Fedratinib was granted FDA approval on August 16, 2019. | Major | 2 | [
[
[
1449,
25,
283
]
],
[
[
1449,
24,
466
],
[
466,
62,
283
]
],
[
[
1449,
64,
600
],
[
600,
24,
283
]
],
[
[
1449,
24,
971
],
[
971,
... | [
[
[
"Simeprevir",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fedratinib"
]
],
[
[
"Simeprevir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Darolutamide"
],
[
"Daroluta... | Simeprevir may cause a moderate interaction that could exacerbate diseases when taken with Darolutamide and Darolutamide may cause a minor interaction that can limit clinical effects when taken with Fedratinib
Simeprevir may lead to a major life threatening interaction when taken with Fluconazole and Fluconazole may ca... |
DB00436 | DB00860 | 323 | 891 | [
"DDInter179",
"DDInter1513"
] | Bendroflumethiazide | Prednisolone | A thiazide diuretic with actions and uses similar to those of hydrochlorothiazide. It has been used in the treatment of familial hyperkalemia, hypertension, edema, and urinary tract disorders. (From Martindale, The Extra Pharmacopoeia, 30th ed, p810) | Prednisolone is a glucocorticoid similar to [cortisol] used for its anti-inflammatory, immunosuppressive, anti-neoplastic, and vasoconstrictive effects. Prednisolone was granted FDA approval on 21 June 1955. | Moderate | 1 | [
[
[
323,
24,
891
]
],
[
[
323,
24,
175
],
[
175,
40,
891
]
],
[
[
323,
24,
167
],
[
167,
1,
891
]
],
[
[
323,
63,
218
],
[
218,
1,
... | [
[
[
"Bendroflumethiazide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Prednisolone"
]
],
[
[
"Bendroflumethiazide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Triamci... | Bendroflumethiazide may cause a moderate interaction that could exacerbate diseases when taken with Triamcinolone and Triamcinolone (Compound) resembles Prednisolone (Compound)
Bendroflumethiazide may cause a moderate interaction that could exacerbate diseases when taken with Hydrocortisone and Hydrocortisone (Compound... |
DB00696 | DB09098 | 826 | 98 | [
"DDInter665",
"DDInter1700"
] | Ergotamine | Somatrem | A vasoconstrictor found in ergot of Central Europe. It is an alpha-1 selective adrenergic agonist and is commonly used in the treatment of migraine disorders. | Despite the ability of almost all contemporary recombinant growth hormones to cause definite and demonstrable increases in growth rate in patients who are administered the drug, the use of these agents continues to be mired in persistent bioethical debate . Such discussion revolves around whether patients' natural disp... | Moderate | 1 | [
[
[
826,
24,
98
]
],
[
[
826,
24,
159
],
[
159,
63,
98
]
],
[
[
826,
25,
609
],
[
609,
24,
98
]
],
[
[
826,
24,
868
],
[
868,
24,
... | [
[
[
"Ergotamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Somatrem"
]
],
[
[
"Ergotamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Larotrectinib"
],
[
... | Ergotamine may cause a moderate interaction that could exacerbate diseases when taken with Larotrectinib and Larotrectinib may cause a moderate interaction that could exacerbate diseases when taken with Somatrem
Ergotamine may lead to a major life threatening interaction when taken with Clarithromycin and Clarithromyci... |
DB00951 | DB09073 | 1,072 | 951 | [
"DDInter986",
"DDInter1379"
] | Isoniazid | Palbociclib | Antibacterial agent used primarily as a tuberculostatic. It remains the treatment of choice for tuberculosis. | Palbociclib is a piperazine pyridopyrimidine that acts in the cell cycle machinery. It is a second generation cyclin-dependent kinase inhibitor selected from a group of pyridopyrimidine compounds due to its favorable physical and pharmaceutical properties. Palbociclib was developed by Pfizer Inc after the discovery tha... | Moderate | 1 | [
[
[
1072,
24,
951
]
],
[
[
1072,
24,
1476
],
[
1476,
63,
951
]
],
[
[
1072,
63,
467
],
[
467,
24,
951
]
],
[
[
1072,
24,
761
],
[
761,
... | [
[
[
"Isoniazid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Palbociclib"
]
],
[
[
"Isoniazid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brigatinib"
],
[
... | Isoniazid may cause a moderate interaction that could exacerbate diseases when taken with Brigatinib and Brigatinib may cause a moderate interaction that could exacerbate diseases when taken with Palbociclib
Isoniazid may cause a moderate interaction that could exacerbate diseases when taken with Simvastatin and Simvas... |
DB00005 | DB01095 | 1,057 | 671 | [
"DDInter687",
"DDInter769"
] | Etanercept | Fluvastatin | Dimeric fusion protein consisting of the extracellular ligand-binding portion of the human 75 kilodalton (p75) tumor necrosis factor receptor (TNFR) linked to the Fc portion of human IgG1.[L14862,A216522] The Fc component of etanercept contains the CH2 domain, the CH3 domain and hinge region, but not the CH1 domain of ... | Fluvastatin is an antilipemic agent that competitively inhibits hydroxymethylglutaryl-coenzyme A (HMG-CoA) reductase. HMG-CoA reductase catalyzes the conversion of HMG-CoA to mevalonic acid, the rate-limiting step in cholesterol biosynthesis. Fluvastatin belongs to a class of medications called statins and is used to r... | Moderate | 1 | [
[
[
1057,
24,
671
]
],
[
[
1057,
24,
788
],
[
788,
40,
671
]
],
[
[
1057,
24,
14
],
[
14,
63,
671
]
],
[
[
1057,
24,
126
],
[
126,
2... | [
[
[
"Etanercept",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fluvastatin"
]
],
[
[
"Etanercept",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pitavastatin"
],
[... | Etanercept may cause a moderate interaction that could exacerbate diseases when taken with Pitavastatin and Pitavastatin (Compound) resembles Fluvastatin (Compound)
Etanercept may cause a moderate interaction that could exacerbate diseases when taken with Rosuvastatin and Rosuvastatin may cause a moderate interaction t... |
DB01039 | DB12500 | 535 | 283 | [
"DDInter718",
"DDInter714"
] | Fenofibrate | Fedratinib | Fenofibrate is a fibric acid derivative like [clofibrate] and [gemfibrozil]. Fenofibrate is used to treat primary hypercholesterolemia, mixed dyslipidemia, severe hypertriglyceridemia.[L8588,L8591] Fenofibrate was granted FDA approval on 31 December 1993. | Fedratinib, also known as SAR302503 and TG101348, is a tyrosine kinase inhibitor used to treat intermediate-2 and high risk primary and secondary myelofibrosis.[A183176,L8090] It is an anilinopyrimidine derivative. Fedratinib was granted FDA approval on August 16, 2019. | Moderate | 1 | [
[
[
535,
24,
283
]
],
[
[
535,
63,
372
],
[
372,
24,
283
]
],
[
[
535,
24,
1411
],
[
1411,
24,
283
]
],
[
[
535,
64,
467
],
[
467,
2... | [
[
[
"Fenofibrate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fedratinib"
]
],
[
[
"Fenofibrate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clofarabine"
],
[... | Fenofibrate may cause a moderate interaction that could exacerbate diseases when taken with Clofarabine and Clofarabine may cause a moderate interaction that could exacerbate diseases when taken with Fedratinib
Fenofibrate may cause a moderate interaction that could exacerbate diseases when taken with Tolbutamide and T... |
DB00215 | DB00398 | 1,230 | 79 | [
"DDInter388",
"DDInter1702"
] | Citalopram | Sorafenib | Citalopram is an antidepressant belonging to the class of selective _serotonin-reuptake inhibitors_ (SSRIs) widely used to treat the symptoms of depression. It is a racemic bicyclic phthalate derivate and is the only compound with a tertiary amine and 2 nitrogen-containing metabolites among all SSRIs.[A261316,A14720] C... | Sorafenib is a bi-aryl urea and an oral multikinase inhibitor. It targets cell surface tyrosine kinase receptors and downstream intracellular kinases that are implicated in tumour cell proliferation and tumour angiogenesis. First approved by the FDA and European Commission in 2007 for the treatment of hepatocellular ca... | Major | 2 | [
[
[
1230,
25,
79
]
],
[
[
1230,
24,
292
],
[
292,
40,
79
]
],
[
[
1230,
6,
10215
],
[
10215,
45,
79
]
],
[
[
1230,
21,
29402
],
[
29402,
... | [
[
[
"Citalopram",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Sorafenib"
]
],
[
[
"Citalopram",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Regorafenib"
],
[
"Regorafeni... | Citalopram may cause a moderate interaction that could exacerbate diseases when taken with Regorafenib and Regorafenib (Compound) resembles Sorafenib (Compound)
Citalopram (Compound) binds CYP2C19 (Gene) and CYP2C19 (Gene) is bound by Sorafenib (Compound)
Citalopram (Compound) causes Hepatobiliary disease (Side Effect)... |
DB00776 | DB12267 | 1,335 | 1,476 | [
"DDInter1360",
"DDInter233"
] | Oxcarbazepine | Brigatinib | Oxcarbazepine is an anti-epileptic medication used in the treatment of partial onset seizures that was first approved for use in the United States in 2000.[L8627,L8630,L8633] It is a structural derivative of [carbamazepine] and exerts a majority of its activity via a pharmacologically active metabolite, MHD, which exis... | Brigatinib, originally named AP26113, is a reversible dual inhibitor of anaplastic lymphoma kinase (ALK) and epidermal growth factor receptor (EGFR). It presents selectivity against the mutant forms of EGFR compared to the wild-type. It also exhibits selectivity against 9 different Crizotinib-resistant mutants of the E... | Moderate | 1 | [
[
[
1335,
24,
1476
]
],
[
[
1335,
24,
1135
],
[
1135,
23,
1476
]
],
[
[
1335,
62,
168
],
[
168,
23,
1476
]
],
[
[
1335,
24,
629
],
[
629,
... | [
[
[
"Oxcarbazepine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brigatinib"
]
],
[
[
"Oxcarbazepine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Naloxegol"
],
... | Oxcarbazepine may cause a moderate interaction that could exacerbate diseases when taken with Naloxegol and Naloxegol may cause a minor interaction that can limit clinical effects when taken with Brigatinib
Oxcarbazepine may cause a minor interaction that can limit clinical effects when taken with Bortezomib and Bortez... |
DB00867 | DB01261 | 1,052 | 170 | [
"DDInter1606",
"DDInter1679"
] | Ritodrine | Sitagliptin | Adrenergic beta-agonist used to control premature labor. | Sitagliptin is an oral dipeptidyl peptidase-4 (DPP-4) inhibitor used in conjunction with diet and exercise to improve glycemic control in patients with type 2 diabetes mellitus[FDA label,A2260,A2255,A2256]. The effect of this medication leads to glucose dependent increases in insulin and decreases in glucagon to improv... | Moderate | 1 | [
[
[
1052,
24,
170
]
],
[
[
1052,
24,
52
],
[
52,
62,
170
]
],
[
[
1052,
23,
708
],
[
708,
63,
170
]
],
[
[
1052,
24,
1616
],
[
1616,
... | [
[
[
"Ritodrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sitagliptin"
]
],
[
[
"Ritodrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dulaglutide"
],
[
... | Ritodrine may cause a moderate interaction that could exacerbate diseases when taken with Dulaglutide and Dulaglutide may cause a minor interaction that can limit clinical effects when taken with Sitagliptin
Ritodrine may cause a minor interaction that can limit clinical effects when taken with Corticotropin and Cortic... |
DB01114 | DB01176 | 272 | 537 | [
"DDInter362",
"DDInter453"
] | Chlorpheniramine | Cyclizine | A histamine H1 antagonist used in allergic reactions, hay fever, rhinitis, urticaria, and asthma. It has also been used in veterinary applications. One of the most widely used of the classical antihistaminics, it generally causes less drowsiness and sedation than promethazine. | A histamine H1 antagonist given by mouth or parenterally for the control of postoperative and drug-induced vomiting and in motion sickness. (From Martindale, The Extra Pharmacopoeia, 30th ed, p935) | Moderate | 1 | [
[
[
272,
24,
537
]
],
[
[
272,
24,
1511
],
[
1511,
63,
537
]
],
[
[
272,
40,
11244
],
[
11244,
1,
537
]
],
[
[
272,
63,
1242
],
[
1242,
... | [
[
[
"Chlorpheniramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cyclizine"
]
],
[
[
"Chlorpheniramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mepenzolate"
... | Chlorpheniramine may cause a moderate interaction that could exacerbate diseases when taken with Mepenzolate and Mepenzolate may cause a moderate interaction that could exacerbate diseases when taken with Cyclizine
Chlorpheniramine (Compound) resembles Pheniramine (Compound) and Pheniramine (Compound) resembles Cyclizi... |
DB06717 | DB08820 | 875 | 1,478 | [
"DDInter778",
"DDInter997"
] | Fosaprepitant | Ivacaftor | Fosaprepitant is an intravenously administered antiemetic drug. It is a prodrug of Aprepitant. It aids in the prevention of acute and delayed nausea and vomiting associated with chemotherapy treatment. | Ivacaftor (also known as Kalydeco or VX-770) is a drug used for the management of Cystic Fibrosis (CF). It is manufactured and distributed by Vertex Pharmaceuticals. It was approved by the Food and Drug Administration on January 31, 2012, and by Health Canada in late 2012. Ivacaftor is administered as a monotherapy and... | Major | 2 | [
[
[
875,
25,
1478
]
],
[
[
875,
21,
29221
],
[
29221,
60,
1478
]
],
[
[
875,
25,
1135
],
[
1135,
62,
1478
]
],
[
[
875,
63,
1411
],
[
1411... | [
[
[
"Fosaprepitant",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ivacaftor"
]
],
[
[
"Fosaprepitant",
"{u} (Compound) causes {v} (Side Effect)",
"Infestation"
],
[
"Infestation",
"{u} (Side Effect) is caused by ... | Fosaprepitant (Compound) causes Infestation (Side Effect) and Infestation (Side Effect) is caused by Ivacaftor (Compound)
Fosaprepitant may lead to a major life threatening interaction when taken with Naloxegol and Naloxegol may cause a minor interaction that can limit clinical effects when taken with Ivacaftor
Fosapre... |
DB06674 | DB09331 | 908 | 745 | [
"DDInter837",
"DDInter478"
] | Golimumab | Daratumumab | Golimumab is a human IgG1қ monoclonal antibody derived from immunizing genetically engineered mice with human TNFα. Golimumab binds and inhibits soluble and transmembrane human TNFα. Increased TNFα is associated with chronic inflammation. Thus golimumab is indicated for use in adults (i) as an adjunct to methotrexate t... | Daratumumab is an immunoglobulin G1 kappa monoclonal antibody developed by Janssen and Genmab. It was first described in the literature in 2010 as a monoclonal antibody that targets CD38+ multiple myeloma cells; the first of its kind. Daratumumab was granted FDA approval on 16 November 2015. It is approved for the trea... | Major | 2 | [
[
[
908,
25,
745
]
],
[
[
908,
64,
139
],
[
139,
24,
745
]
],
[
[
908,
63,
597
],
[
597,
24,
745
]
],
[
[
908,
25,
287
],
[
287,
63,... | [
[
[
"Golimumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Daratumumab"
]
],
[
[
"Golimumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Zidovudine"
],
[
"Zidovudine",
"{u} ma... | Golimumab may lead to a major life threatening interaction when taken with Zidovudine and Zidovudine may cause a moderate interaction that could exacerbate diseases when taken with Daratumumab
Golimumab may cause a moderate interaction that could exacerbate diseases when taken with Chloramphenicol and Chloramphenicol m... |
DB00950 | DB09104 | 1,413 | 286 | [
"DDInter732",
"DDInter1118"
] | Fexofenadine | Magnesium hydroxide | Fexofenadine is an over-the-counter second-generation antihistamine used in the treatment of various allergic symptoms. It is selective for the H<sub>1</sub> receptor, carries little-to-no activity at off-targets, and does not cross the blood-brain barrier - this is in contrast to previous first-generation antihistamin... | Magnesium hydroxide is an inorganic compound. It is naturally found as the mineral brucite. Magnesium hydroxide can be used as an antacid or a laxative in either an oral liquid suspension or chewable tablet form. Additionally, magnesium hydroxide has smoke suppressing and flame retardant properties and is thus used com... | Moderate | 1 | [
[
[
1413,
24,
286
]
],
[
[
1413,
63,
954
],
[
954,
23,
286
]
],
[
[
1413,
24,
1468
],
[
1468,
23,
286
]
],
[
[
1413,
24,
868
],
[
868,
... | [
[
[
"Fexofenadine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium hydroxide"
]
],
[
[
"Fexofenadine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Quinapril"
... | Fexofenadine may cause a moderate interaction that could exacerbate diseases when taken with Quinapril and Quinapril may cause a minor interaction that can limit clinical effects when taken with Magnesium hydroxide
Fexofenadine may cause a moderate interaction that could exacerbate diseases when taken with Ponatinib an... |
DB00802 | DB00902 | 1,322 | 104 | [
"DDInter43",
"DDInter1168"
] | Alfentanil | Methdilazine | A short-acting opioid anesthetic and analgesic derivative of fentanyl. It produces an early peak analgesic effect and fast recovery of consciousness. Alfentanil is effective as an anesthetic during surgery, for supplementation of analgesia during surgical procedures, and as an analgesic for critically ill patients. | Methdilazine is a phenothiazine compound with antihistaminic activity. It is used in the treatment of various dermatoses to relieve pruritus. | Moderate | 1 | [
[
[
1322,
24,
104
]
],
[
[
1322,
63,
13
],
[
13,
24,
104
]
],
[
[
1322,
24,
820
],
[
820,
1,
104
]
],
[
[
1322,
24,
537
],
[
537,
40... | [
[
[
"Alfentanil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methdilazine"
]
],
[
[
"Alfentanil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cyproheptadine"
],
... | Alfentanil may cause a moderate interaction that could exacerbate diseases when taken with Cyproheptadine and Cyproheptadine may cause a moderate interaction that could exacerbate diseases when taken with Methdilazine
Alfentanil may cause a moderate interaction that could exacerbate diseases when taken with Alimemazine... |
DB00270 | DB01164 | 1,428 | 803 | [
"DDInter993",
"DDInter272"
] | Isradipine | Calcium chloride | Isradipine belongs to the dihydropyridine (DHP) class of calcium channel blockers (CCBs), the most widely used class of CCBs. It is structurally related to felodipine, nifedipine, and nimodipine and is the most potent calcium-channel blocking agent of the DHP class. Isradipine binds to calcium channels with high affini... | Calcium chloride is an ionic compound of calcium and chlorine. It is highly soluble in water and it is deliquescent. It is a salt that is solid at room temperature, and it behaves as a typical ionic halide. It has several common applications such as brine for refrigeration plants, ice and dust control on roads, and in ... | Moderate | 1 | [
[
[
1428,
24,
803
]
],
[
[
1428,
21,
29196
],
[
29196,
60,
803
]
],
[
[
1428,
1,
84
],
[
84,
24,
803
]
],
[
[
1428,
40,
854
],
[
854,
... | [
[
[
"Isradipine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Calcium chloride"
]
],
[
[
"Isradipine",
"{u} (Compound) causes {v} (Side Effect)",
"Paraesthesia"
],
[
"Paraesthesia",
"{u} (Side Eff... | Isradipine (Compound) causes Paraesthesia (Side Effect) and Paraesthesia (Side Effect) is caused by Calcium chloride (Compound)
Isradipine (Compound) resembles Nisoldipine (Compound) and Nisoldipine may cause a moderate interaction that could exacerbate diseases when taken with Calcium chloride
Isradipine (Compound) re... |
DB00526 | DB08904 | 1,555 | 375 | [
"DDInter1355",
"DDInter342"
] | Oxaliplatin | Certolizumab pegol | Oxaliplatin is a platinum-based chemotherapy drug in the same family as cisplatin and carboplatin. Compared to cisplatin the two amine groups are replaced by diamino cyclohexane (DACH) group to provide a greater antitumor effect. However, this leads to poorer water solubility, which was compensated by the addition of t... | Certolizumab pegol is a pegylated monoclonal antibody against the tumor necrosis factor-alpha (TNF-alpha). It is formed with a humanized Fab fragment of 50 kDa, from an IgG 1 isotype, fused to a 40 kDa polyethylene glycol moiety replacing the Fc antibody region. The absence of the Fc region was ideated to prevent compl... | Major | 2 | [
[
[
1555,
25,
375
]
],
[
[
1555,
63,
1461
],
[
1461,
23,
375
]
],
[
[
1555,
24,
231
],
[
231,
24,
375
]
],
[
[
1555,
24,
200
],
[
200,
... | [
[
[
"Oxaliplatin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Certolizumab pegol"
]
],
[
[
"Oxaliplatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vitamin E"
],
[
"V... | Oxaliplatin may cause a moderate interaction that could exacerbate diseases when taken with Vitamin E and Vitamin E may cause a minor interaction that can limit clinical effects when taken with Certolizumab pegol
Oxaliplatin may cause a moderate interaction that could exacerbate diseases when taken with Stavudine and S... |
DB00959 | DB13179 | 1,486 | 68 | [
"DDInter1191",
"DDInter1882"
] | Methylprednisolone | Troleandomycin | Methylprednisolone is a [prednisolone] derivative glucocorticoid with higher potency than [prednisone]. It was first described in the literature in the late 1950s.[A188811,A188814] Methylprednisolone was granted FDA approval on 24 October 1957. In the outbreak of COVID-19, low dose methylprednisolone-based therapy was ... | A macrolide antibiotic that is similar to erythromycin. | Major | 2 | [
[
[
1486,
25,
68
]
],
[
[
1486,
63,
1101
],
[
1101,
23,
68
]
],
[
[
1486,
24,
1662
],
[
1662,
24,
68
]
],
[
[
1486,
40,
251
],
[
251,
... | [
[
[
"Methylprednisolone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Troleandomycin"
]
],
[
[
"Methylprednisolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bexarotene"
],
... | Methylprednisolone may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and Bexarotene may cause a minor interaction that can limit clinical effects when taken with Troleandomycin
Methylprednisolone may cause a moderate interaction that could exacerbate diseases when taken with Pic... |
DB00471 | DB00834 | 201 | 932 | [
"DDInter1242",
"DDInter1215"
] | Montelukast | Mifepristone | Montelukast was first approved for clinical use by the US FDA in 1998 as Merck's brand name Singulair. The medication is a member of the leukotriene receptor antagonist (LTRA) category of drugs.[L6301,L6304,L6307,L6310,L6325,L6328,L6331] Although capable of demonstrating effectiveness, the use of such LTRAs like montel... | Mifepristone is a progestational and glucocorticoid hormone antagonist. Its inhibition of progesterone induces bleeding during the luteal phase and in early pregnancy by releasing endogenous prostaglandins from the endometrium or decidua. As a glucocorticoid receptor antagonist, the drug has been used to treat hypercor... | Moderate | 1 | [
[
[
201,
24,
932
]
],
[
[
201,
6,
8374
],
[
8374,
45,
932
]
],
[
[
201,
21,
28976
],
[
28976,
60,
932
]
],
[
[
201,
63,
1101
],
[
1101,
... | [
[
[
"Montelukast",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mifepristone"
]
],
[
[
"Montelukast",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compoun... | Montelukast (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Mifepristone (Compound)
Montelukast (Compound) causes Erythema nodosum (Side Effect) and Erythema nodosum (Side Effect) is caused by Mifepristone (Compound)
Montelukast may cause a moderate interaction that could exacerbate diseases when taken wit... |
DB00661 | DB06626 | 122 | 263 | [
"DDInter1928",
"DDInter147"
] | Verapamil | Axitinib | Verapamil is a phenylalkylamine calcium channel blocker used in the treatment of high blood pressure, heart arrhythmias, and angina, and was the first calcium channel antagonist to be introduced into therapy in the early 1960s. It is a member of the non-dihydropyridine class of calcium channel blockers, which includes ... | Axitinib is a second generation tyrosine kinase inhibitor that works by selectively inhibiting vascular endothelial growth factor receptors (VEGFR-1, VEGFR-2, VEGFR-3). Through this mechanism of action, axitinib blocks angiogenesis, tumour growth and metastases. It is reported to exhibit potency that is 50-450 times hi... | Moderate | 1 | [
[
[
122,
24,
263
]
],
[
[
122,
63,
752
],
[
752,
23,
263
]
],
[
[
122,
63,
702
],
[
702,
24,
263
]
],
[
[
122,
24,
392
],
[
392,
24,... | [
[
[
"Verapamil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Axitinib"
]
],
[
[
"Verapamil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cimetidine"
],
[
... | Verapamil may cause a moderate interaction that could exacerbate diseases when taken with Cimetidine and Cimetidine may cause a minor interaction that can limit clinical effects when taken with Axitinib
Verapamil may cause a moderate interaction that could exacerbate diseases when taken with Anagrelide and Anagrelide m... |
DB00987 | DB01101 | 1,224 | 60 | [
"DDInter461",
"DDInter285"
] | Cytarabine (liposomal) | Capecitabine | Cytarabine can cause developmental toxicity according to an independent committee of scientific and health experts. | Capecitabine is an orally-administered chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. Capecitabine is a prodrug, that is enzymatically converted to fluorouracil (antimetabolite) in the tumor, where it inhibits DNA synthesis and slows growth of tumor tissue. | Moderate | 1 | [
[
[
1224,
24,
60
]
],
[
[
1224,
6,
2358
],
[
2358,
45,
60
]
],
[
[
1224,
54,
19218
],
[
19218,
15,
60
]
],
[
[
1224,
23,
872
],
[
872,
... | [
[
[
"Cytarabine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Capecitabine"
]
],
[
[
"Cytarabine",
"{u} (Compound) binds {v} (Gene)",
"CDA"
],
[
"CDA",
"{u} (Gene) is bound by {v} (Compound)",
... | Cytarabine may cause a moderate interaction that could exacerbate diseases when taken with Capecitabine
Cytarabine (Compound) binds CDA (Gene) and CDA (Gene) is bound by Capecitabine (Compound)
Cytarabine (Compound) is included by Nucleic Acid Synthesis Inhibitors (Pharmacologic Class) and Nucleic Acid Synthesis Inhibi... |
DB00531 | DB01764 | 450 | 805 | [
"DDInter456",
"DDInter469"
] | Cyclophosphamide | Dalfopristin | Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the liver to form the active aldophosphamide. It has been used in the treatment of lymphoma and leukemia. Its side effect, alopecia, has been used for defleecing sheep. Cyclophosphamide may also cause steril... | Dalfopristin is a combination of two antibiotics (Dalfopristin and quinupristin) used to treat infections by staphylococci and by vancomycin-resistant Enterococcus faecium. It is not effective against Enterococcus faecalis infections. Dalfopristin inhibits the early phase of protein synthesis in the bacterial ribosome ... | Moderate | 1 | [
[
[
450,
24,
805
]
],
[
[
450,
6,
8374
],
[
8374,
45,
805
]
],
[
[
450,
24,
473
],
[
473,
24,
805
]
],
[
[
450,
24,
1619
],
[
1619,
... | [
[
[
"Cyclophosphamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dalfopristin"
]
],
[
[
"Cyclophosphamide",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v... | Cyclophosphamide (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Dalfopristin (Compound)
Cyclophosphamide may cause a moderate interaction that could exacerbate diseases when taken with Repaglinide and Repaglinide may cause a moderate interaction that could exacerbate diseases when taken with Dalfopristin
... |
DB01233 | DB01591 | 1,311 | 667 | [
"DDInter1197",
"DDInter1696"
] | Metoclopramide | Solifenacin | Diabetic gastroparesis is a condition that causes frequent nausea and vomiting, which has a negative impact on quality of life and poses a significant burden on the healthcare system. Metoclopramide is a dopamine antagonist used to treat nausea and vomiting that may be associated with diabetic gastroparesis in addition... | Solifenacin is a competitive muscarinic receptor antagonist indicated to treat an overactive bladder with urinary incontinence, urgency, and frequency. It has a long duration of action as it is usually taken once daily. Solifenacin was granted FDA approval on 19 November 2004. | Moderate | 1 | [
[
[
1311,
24,
667
]
],
[
[
1311,
6,
7992
],
[
7992,
45,
667
]
],
[
[
1311,
21,
28743
],
[
28743,
60,
667
]
],
[
[
1311,
24,
830
],
[
830,
... | [
[
[
"Metoclopramide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Solifenacin"
]
],
[
[
"Metoclopramide",
"{u} (Compound) binds {v} (Gene)",
"CHRM1"
],
[
"CHRM1",
"{u} (Gene) is bound by {v} (Comp... | Metoclopramide (Compound) binds CHRM1 (Gene) and CHRM1 (Gene) is bound by Solifenacin (Compound)
Metoclopramide (Compound) causes Atrial fibrillation (Side Effect) and Atrial fibrillation (Side Effect) is caused by Solifenacin (Compound)
Metoclopramide may cause a moderate interaction that could exacerbate diseases whe... |
DB00514 | DB15093 | 506 | 1,654 | [
"DDInter527",
"DDInter1698"
] | Dextromethorphan | Somapacitan | Dextromethorphan is a levorphanol derivative and codeine analog commonly used as a cough suppressant and also a drug of abuse. Although similar in structure to other opioids, it has minimal interaction with opioid receptors. Dextromethorphan was granted FDA approval before 3 December 1957.[A215412,L14997] | Somapacitan, also known as NNC0195-0092, is a growth hormone analog indicated to treat adults with growth hormone deficiency.[A219126,L15661] This human growth hormone analog differs by the creation of an albumin binding site, and prolonging the effect so that it requires weekly dosing rather than daily. Somapacitan wa... | Moderate | 1 | [
[
[
506,
24,
1654
]
],
[
[
506,
25,
1387
],
[
1387,
24,
1654
]
],
[
[
506,
63,
530
],
[
530,
24,
1654
]
],
[
[
506,
24,
1419
],
[
1419,
... | [
[
[
"Dextromethorphan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Somapacitan"
]
],
[
[
"Dextromethorphan",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Terbinafine"
],
[
... | Dextromethorphan may lead to a major life threatening interaction when taken with Terbinafine and Terbinafine may cause a moderate interaction that could exacerbate diseases when taken with Somapacitan
Dextromethorphan may cause a moderate interaction that could exacerbate diseases when taken with Dronabinol and Dronab... |
DB01097 | DB06603 | 1,377 | 39 | [
"DDInter1033",
"DDInter1387"
] | Leflunomide | Panobinostat | Leflunomide is a pyrimidine synthesis inhibitor belonging to the DMARD (disease-modifying antirheumatic drug) class of drugs, which are chemically and pharmacologically very heterogeneous. Leflunomide was approved by FDA and in many other countries (e.g., Canada, Europe) in 1999. | Panobinostat is an oral deacetylace (DAC) inhibitor approved on February 23, 2015 by the FDA for the treatment of multiple myeloma. The approval was accelerated based on progression-free survival, therefore confirmatory trials by the sponsor to demonstrate clinical efficacy in multiple myeloma treatment are in progress... | Major | 2 | [
[
[
1377,
25,
39
]
],
[
[
1377,
63,
112
],
[
112,
23,
39
]
],
[
[
1377,
64,
912
],
[
912,
24,
39
]
],
[
[
1377,
24,
221
],
[
221,
63... | [
[
[
"Leflunomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Panobinostat"
]
],
[
[
"Leflunomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metronidazole"
],
[
"Met... | Leflunomide may cause a moderate interaction that could exacerbate diseases when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Panobinostat
Leflunomide may lead to a major life threatening interaction when taken with Interferon beta-1a and Inter... |
DB00928 | DB14783 | 1,426 | 287 | [
"DDInter148",
"DDInter574"
] | Azacitidine | Diroximel fumarate | Azacitidine is a pyrimidine nucleoside analogue with anti-neoplastic activity. It differs from cytosine by the presence of nitrogen in the C5-position, key in its hypomethylating activity.[A1406,A1413,A1415] Two main mechanisms of action have been proposed for azacitidine. One of them is the induction of cytotoxicity. ... | Multiple Sclerosis (MS) is a chronic, debilitating neurological disease that can lead to profound cognitive and physical symptoms, severely affecting quality of life. It is the main cause of neurological disability not caused by trauma in the young adult population of both North America and Europe. Relapsing-remitting ... | Moderate | 1 | [
[
[
1426,
24,
287
]
],
[
[
1426,
24,
384
],
[
384,
24,
287
]
],
[
[
1426,
63,
599
],
[
599,
24,
287
]
],
[
[
1426,
1,
1224
],
[
1224,
... | [
[
[
"Azacitidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diroximel fumarate"
]
],
[
[
"Azacitidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Idelalisib"
]... | Azacitidine may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib and Idelalisib may cause a moderate interaction that could exacerbate diseases when taken with Diroximel fumarate
Azacitidine may cause a moderate interaction that could exacerbate diseases when taken with Alemtuzumab... |
DB00701 | DB01234 | 1,091 | 1,220 | [
"DDInter90",
"DDInter513"
] | Amprenavir | Dexamethasone | Amprenavir is a protease inhibitor used to treat HIV infection. | Dexamethasone, or MK-125, is a corticosteroid fluorinated at position 9 used to treat endocrine, rheumatic, collagen, dermatologic, allergic, ophthalmic, gastrointestinal, respiratory, hematologic, neoplastic, edematous, and other conditions. Developed in 1957, it is structurally similar to other corticosteroids like [... | Moderate | 1 | [
[
[
1091,
24,
1220
]
],
[
[
1091,
63,
870
],
[
870,
1,
1220
]
],
[
[
1091,
64,
175
],
[
175,
40,
1220
]
],
[
[
1091,
24,
167
],
[
167,
... | [
[
[
"Amprenavir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dexamethasone"
]
],
[
[
"Amprenavir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fludrocortisone"
],
... | Amprenavir may cause a moderate interaction that could exacerbate diseases when taken with Fludrocortisone and Fludrocortisone (Compound) resembles Dexamethasone (Compound)
Amprenavir may lead to a major life threatening interaction when taken with Triamcinolone and Triamcinolone (Compound) resembles Dexamethasone (Com... |
DB01097 | DB05528 | 1,377 | 1,070 | [
"DDInter1033",
"DDInter1228"
] | Leflunomide | Mipomersen | Leflunomide is a pyrimidine synthesis inhibitor belonging to the DMARD (disease-modifying antirheumatic drug) class of drugs, which are chemically and pharmacologically very heterogeneous. Leflunomide was approved by FDA and in many other countries (e.g., Canada, Europe) in 1999. | Mipomersen sodium, which was known as the investigational drug, isis-301012, is the salt form of a synthetic phosphorothioate oligonucleotide. Mipomersen sodium prevents the formation of apo B-100, resulting in a decrease in the levels of apolipoprotein B (apo B), low density lipoprotein (LDL), and total cholesterol. M... | Major | 2 | [
[
[
1377,
25,
1070
]
],
[
[
1377,
25,
292
],
[
292,
64,
1070
]
],
[
[
1377,
64,
1512
],
[
1512,
25,
1070
]
],
[
[
1377,
25,
14
],
[
14,
... | [
[
[
"Leflunomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Mipomersen"
]
],
[
[
"Leflunomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Regorafenib"
],
[
"Regorafenib",
"{... | Leflunomide may lead to a major life threatening interaction when taken with Regorafenib and Regorafenib may lead to a major life threatening interaction when taken with Mipomersen
Leflunomide may lead to a major life threatening interaction when taken with Diclofenac and Diclofenac may lead to a major life threatening... |
DB01365 | DB09080 | 280 | 144 | [
"DDInter1151",
"DDInter1331"
] | Mephentermine | Olodaterol | A sympathomimetic agent with mainly indirect effects on adrenergic receptors. It is used to maintain blood pressure in hypotensive states, for example, following spinal anesthesia. Although the central stimulant effects of mephentermine are much less than those of amphetamine, its use may lead to amphetamine-type depen... | Olodaterol is a novel, long-acting beta2-adrenergic agonist (LABA) that exerts its pharmacological effect by binding and activating beta2-adrenergic receptors located primarily in the lungs. Beta2-adrenergic receptors are membrane-bound receptors that are normally activated by endogenous epinephrine whose signalling, v... | Moderate | 1 | [
[
[
280,
24,
144
]
],
[
[
280,
40,
1445
],
[
1445,
24,
144
]
],
[
[
280,
63,
1048
],
[
1048,
24,
144
]
],
[
[
280,
1,
80
],
[
80,
24... | [
[
[
"Mephentermine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Olodaterol"
]
],
[
[
"Mephentermine",
"{u} (Compound) resembles {v} (Compound)",
"Pseudoephedrine"
],
[
"Pseudoephedrine",
"{u} may... | Mephentermine (Compound) resembles Pseudoephedrine (Compound) and Pseudoephedrine may cause a moderate interaction that could exacerbate diseases when taken with Olodaterol
Mephentermine may cause a moderate interaction that could exacerbate diseases when taken with Doxapram and Doxapram may cause a moderate interactio... |
DB06273 | DB11601 | 980 | 1,270 | [
"DDInter1824",
"DDInter1889"
] | Tocilizumab | Tuberculin purified protein derivative | Tocilizumab is a recombinant humanized monoclonal antibody IL-6 receptor inhibitor used to treat inflammatory and autoimmune conditions. It was first described in the literature in 2003 when Chugai, a subsidiary of Roche began developing IL-6 inhibiting monoclonal antibodies. Tocilizumab was granted FDA approval on 8 J... | Tuberculin Purified Protein Derivative (PPD) is a sterile aqueous solution of a purified protein fraction for intradermal administration as an aid in the diagnosis of tuberculosis. The diagnostic test is commonly referred to as the Mantoux test which serves to minimize the risk of transmission of infection with *Mycoba... | Moderate | 1 | [
[
[
980,
24,
1270
]
],
[
[
980,
24,
350
],
[
350,
24,
1270
]
],
[
[
980,
64,
1531
],
[
1531,
24,
1270
]
],
[
[
980,
63,
1555
],
[
1555,
... | [
[
[
"Tocilizumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tuberculin purified protein derivative"
]
],
[
[
"Tocilizumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
... | Tocilizumab may cause a moderate interaction that could exacerbate diseases when taken with Carfilzomib and Carfilzomib may cause a moderate interaction that could exacerbate diseases when taken with Tuberculin purified protein derivative
Tocilizumab may lead to a major life threatening interaction when taken with Cana... |
DB00431 | DB11640 | 1,503 | 1,267 | [
"DDInter1072",
"DDInter64"
] | Lindane | Amifampridine | An organochlorine insecticide that has been used as a pediculicide and a scabicide. Lindane has been banned in California, United Kingdom, Australia, and many western countries due to concerns about neurotoxicity and adverse effects on the environment. In Canada, Lindane is not recommmended as a first-line therapy due ... | Amifampridine, or 3,4-diaminopyridine (3,4-DAP), is a quaternary ammonium compound that blocks presynaptic potassium channels, and subsequently prolongs the action potential and increases presynaptic calcium concentrations . It was first discovered in Scotland in the 1970s and its clinical effectiveness for neuromuscul... | Moderate | 1 | [
[
[
1503,
24,
1267
]
],
[
[
1503,
24,
407
],
[
407,
24,
1267
]
],
[
[
1503,
63,
999
],
[
999,
24,
1267
]
],
[
[
1503,
24,
913
],
[
913,
... | [
[
[
"Lindane",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Amifampridine"
]
],
[
[
"Lindane",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Opium"
],
[
"Opi... | Lindane may cause a moderate interaction that could exacerbate diseases when taken with Opium and Opium may cause a moderate interaction that could exacerbate diseases when taken with Amifampridine
Lindane may cause a moderate interaction that could exacerbate diseases when taken with Thiethylperazine and Thiethylperaz... |
DB01177 | DB01254 | 77 | 1,213 | [
"DDInter904",
"DDInter484"
] | Idarubicin | Dasatinib | An orally administered anthracycline antineoplastic. The compound has shown activity against breast cancer, lymphomas and leukemias, together with the potential for reduced cardiac toxicity. | Dasatinib is an orally available multikinase inhibitor indicated for the treatment of Philadelphia chromosome (Ph)-positive leukemias.[A2224,L45171] Ph is a chromosomal abnormality found in patients with chronic myelogenous leukemia (CML) and acute lymphocytic leukemia (ALL), where the ABL tyrosine kinase and the break... | Moderate | 1 | [
[
[
77,
24,
1213
]
],
[
[
77,
5,
11555
],
[
11555,
44,
1213
]
],
[
[
77,
18,
2030
],
[
2030,
45,
1213
]
],
[
[
77,
7,
7580
],
[
7580,
... | [
[
[
"Idarubicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dasatinib"
]
],
[
[
"Idarubicin",
"{u} (Compound) treats {v} (Disease)",
"hematologic cancer"
],
[
"hematologic cancer",
"{u} (Disease... | Idarubicin (Compound) treats hematologic cancer (Disease) and hematologic cancer (Disease) is treated by Dasatinib (Compound)
Idarubicin (Compound) downregulates ABL1 (Gene) and ABL1 (Gene) is bound by Dasatinib (Compound)
Idarubicin (Compound) upregulates TESK1 (Gene) and TESK1 (Gene) is bound by Dasatinib (Compound)
... |
DB08881 | DB09280 | 868 | 1,604 | [
"DDInter1925",
"DDInter1101"
] | Vemurafenib | Lumacaftor | Vemurafenib is a competitive kinase inhibitor with activity against BRAF kinase with mutations like V600E. It exerts its function by binding to the ATP-binding domain of the mutant BRAF. Vemurafenib was co-developed by Roche and Plexxikon and it obtained its FDA approval on August 17, 2011, under the company Hoffmann L... | Lumacaftor is a drug used in combination with as the fixed dose combination product Orkambi for the management of Cystic Fibrosis (CF) in patients aged 6 years and older. Cystic Fibrosis is an autosomal recessive disorder caused by one of several different mutations in the gene for the Cystic Fibrosis Transmembrane Con... | Major | 2 | [
[
[
868,
25,
1604
]
],
[
[
868,
63,
573
],
[
573,
24,
1604
]
],
[
[
868,
24,
1427
],
[
1427,
24,
1604
]
],
[
[
868,
64,
1251
],
[
1251,
... | [
[
[
"Vemurafenib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lumacaftor"
]
],
[
[
"Vemurafenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fesoterodine"
],
[
"Fesote... | Vemurafenib may cause a moderate interaction that could exacerbate diseases when taken with Fesoterodine and Fesoterodine may cause a moderate interaction that could exacerbate diseases when taken with Lumacaftor
Vemurafenib may cause a moderate interaction that could exacerbate diseases when taken with Vortioxetine an... |
DB00843 | DB06663 | 479 | 1,154 | [
"DDInter583",
"DDInter1398"
] | Donepezil | Pasireotide | In 2016, the global burden of dementia was estimated to be 43.8 million, demonstrating a significant increase from a global prevalence of 20.2 million in 1990. Donepezil, also known as Aricept, is a piperidine derivative acetylcholinesterase inhibitor used in the management of the dementia of Alzheimer's Disease, and i... | Pasireotide is a synthetic long-acting cyclic hexapeptide with somatostatin-like activity. It is marketed as a diaspartate salt called Signifor, which is used in the treatment of Cushing's disease. | Moderate | 1 | [
[
[
479,
24,
1154
]
],
[
[
479,
21,
28900
],
[
28900,
60,
1154
]
],
[
[
479,
24,
112
],
[
112,
23,
1154
]
],
[
[
479,
24,
1662
],
[
1662,
... | [
[
[
"Donepezil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pasireotide"
]
],
[
[
"Donepezil",
"{u} (Compound) causes {v} (Side Effect)",
"Abdominal pain"
],
[
"Abdominal pain",
"{u} (Side Effect... | Donepezil (Compound) causes Abdominal pain (Side Effect) and Abdominal pain (Side Effect) is caused by Pasireotide (Compound)
Donepezil may cause a moderate interaction that could exacerbate diseases when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken... |
DB00860 | DB01009 | 891 | 935 | [
"DDInter1513",
"DDInter1009"
] | Prednisolone | Ketoprofen | Prednisolone is a glucocorticoid similar to [cortisol] used for its anti-inflammatory, immunosuppressive, anti-neoplastic, and vasoconstrictive effects. Prednisolone was granted FDA approval on 21 June 1955. | Ketoprofen, a propionic acid derivative, is a nonsteroidal anti-inflammatory agent (NSAIA) with analgesic and antipyretic properties. | Moderate | 1 | [
[
[
891,
24,
935
]
],
[
[
891,
63,
1523
],
[
1523,
40,
935
]
],
[
[
891,
63,
1274
],
[
1274,
24,
935
]
],
[
[
891,
24,
1263
],
[
1263,
... | [
[
[
"Prednisolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ketoprofen"
]
],
[
[
"Prednisolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Labetalol"
],
[... | Prednisolone may cause a moderate interaction that could exacerbate diseases when taken with Labetalol and Labetalol (Compound) resembles Ketoprofen (Compound)
Prednisolone may cause a moderate interaction that could exacerbate diseases when taken with Flurbiprofen and Flurbiprofen may cause a moderate interaction that... |
DB00413 | DB00470 | 1,346 | 530 | [
"DDInter1505",
"DDInter601"
] | Pramipexole | Dronabinol | Pramipexole is a drug used to treat the symptoms of Parkinson's Disease (PD). It is a _non-ergot dopamine agonist_ drug that is efficacious in treating various Parkinson's symptoms such as tremor, rigidity, and bradykinesia (slow movement). It was first approved by the FDA in 1997. Parkinson's Disease is one of the mos... | Dronabinol (marketed as Marinol) is a synthetic form of delta-9-tetrahydrocannabinol (Δ⁹-THC), the primary psychoactive component of cannabis (marijuana). THC demonstrates its effects through weak partial agonist activity at Cannabinoid-1 (CB1R) and Cannabinoid-2 (CB2R) receptors, which results in the well-known effect... | Moderate | 1 | [
[
[
1346,
24,
530
]
],
[
[
1346,
24,
1614
],
[
1614,
40,
530
]
],
[
[
1346,
21,
29226
],
[
29226,
60,
530
]
],
[
[
1346,
63,
701
],
[
701,... | [
[
[
"Pramipexole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dronabinol"
]
],
[
[
"Pramipexole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nabilone"
],
[
... | Pramipexole may cause a moderate interaction that could exacerbate diseases when taken with Nabilone and Nabilone (Compound) resembles Dronabinol (Compound)
Pramipexole (Compound) causes Sinusitis (Side Effect) and Sinusitis (Side Effect) is caused by Dronabinol (Compound)
Pramipexole may cause a moderate interaction t... |
DB00651 | DB00801 | 746 | 1,563 | [
"DDInter613",
"DDInter850"
] | Dyphylline | Halazepam | Dyphylline is a theophylline derivative with broncho- and vasodilator properties. It is typically used in the management of asthma, cardiac dyspnea, and bronchitis. | Halazepam is a _benzodiazepine_ derivative drug exerting anxiolytic, anticonvulsant, sedative, a muscle relaxing effects.[A1212, A178114] It has been shown to be less toxic than chlordiazepoxide or diazepam. This drug is no longer marketed in the United States, and was withdrawn by _Schering_, its manufacturer, in 2009... | Minor | 0 | [
[
[
746,
23,
1563
]
],
[
[
746,
23,
686
],
[
686,
1,
1563
]
],
[
[
746,
62,
902
],
[
902,
40,
1563
]
],
[
[
746,
62,
523
],
[
523,
1... | [
[
[
"Dyphylline",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Halazepam"
]
],
[
[
"Dyphylline",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Oxazepam"
],
[
"Ox... | Dyphylline may cause a minor interaction that can limit clinical effects when taken with Oxazepam and Oxazepam (Compound) resembles Halazepam (Compound)
Dyphylline may cause a minor interaction that can limit clinical effects when taken with Clobazam and Clobazam (Compound) resembles Halazepam (Compound)
Dyphylline may... |
DB00086 | DB00691 | 1,167 | 1,058 | [
"DDInter1712",
"DDInter1237"
] | Streptokinase | Moexipril | Streptokinase, is a sterile, purified preparation of a bacterial protein elaborated by group C (beta) -hemolytic streptococci. | Moexipril is a non-sulfhydryl containing precursor of the active angiotensin-converting enzyme (ACE) inhibitor moexiprilat. It is used to treat high blood pressure (hypertension). It works by relaxing blood vessels, causing them to widen. Lowering high blood pressure helps prevent strokes, heart attacks and kidney prob... | Moderate | 1 | [
[
[
1167,
24,
1058
]
],
[
[
1167,
24,
1638
],
[
1638,
1,
1058
]
],
[
[
1167,
24,
954
],
[
954,
40,
1058
]
],
[
[
1167,
24,
714
],
[
714,
... | [
[
[
"Streptokinase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Moexipril"
]
],
[
[
"Streptokinase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trandolapril"
],
... | Streptokinase may cause a moderate interaction that could exacerbate diseases when taken with Trandolapril and Trandolapril (Compound) resembles Moexipril (Compound)
Streptokinase may cause a moderate interaction that could exacerbate diseases when taken with Quinapril and Quinapril (Compound) resembles Moexipril (Comp... |
DB00348 | DB00794 | 254 | 759 | [
"DDInter1300",
"DDInter1521"
] | Nitisinone | Primidone | Nitisinone is a synthetic reversible inhibitor of 4-hydroxyphenylpyruvate dioxygenase. It is used in the treatment of hereditary tyrosinemia type 1. It is sold under the brand name Orfadin. | Primidone is an anticonvulsant used to treat essential tremor as well as grand mal, psychomotor, and focal epileptic seizures. Primidone was developed by J Yule Bogue and H C Carrington in 1949. Primidone was granted FDA Approval on 8 March 1954. | Moderate | 1 | [
[
[
254,
24,
759
]
],
[
[
254,
24,
697
],
[
697,
40,
759
]
],
[
[
254,
63,
362
],
[
362,
1,
759
]
],
[
[
254,
21,
28847
],
[
28847,
... | [
[
[
"Nitisinone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Primidone"
]
],
[
[
"Nitisinone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phenobarbital"
],
[
... | Nitisinone may cause a moderate interaction that could exacerbate diseases when taken with Phenobarbital and Phenobarbital (Compound) resembles Primidone (Compound)
Nitisinone may cause a moderate interaction that could exacerbate diseases when taken with Phenytoin and Phenytoin (Compound) resembles Primidone (Compound... |
DB00712 | DB11166 | 1,274 | 18 | [
"DDInter764",
"DDInter104"
] | Flurbiprofen (ophthalmic) | Antithrombin Alfa | Flurbiprofen can cause developmental toxicity and female reproductive toxicity according to state or federal government labeling requirements. | Antithrombin Alfa is a recombinant antithrombin , an anticoagulant, that is used for the prevention of thromboembolic events in patients that have hereditary deficiency of antithrombin in high risk situations. | Moderate | 1 | [
[
[
1274,
24,
18
]
],
[
[
1274,
24,
714
],
[
714,
24,
18
]
],
[
[
1274,
35,
848
],
[
848,
24,
18
]
],
[
[
1274,
24,
738
],
[
738,
63... | [
[
[
"Flurbiprofen",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Antithrombin Alfa"
]
],
[
[
"Flurbiprofen",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Iloprost"
],... | Flurbiprofen may cause a moderate interaction that could exacerbate diseases when taken with Antithrombin Alfa
Flurbiprofen may cause a moderate interaction that could exacerbate diseases when taken with Iloprost and Iloprost may cause a moderate interaction that could exacerbate diseases when taken with Antithrombin A... |
DB06273 | DB08901 | 980 | 1,468 | [
"DDInter1824",
"DDInter1492"
] | Tocilizumab | Ponatinib | Tocilizumab is a recombinant humanized monoclonal antibody IL-6 receptor inhibitor used to treat inflammatory and autoimmune conditions. It was first described in the literature in 2003 when Chugai, a subsidiary of Roche began developing IL-6 inhibiting monoclonal antibodies. Tocilizumab was granted FDA approval on 8 J... | Ponatinib is a novel Bcr-Abl tyrosine kinase inhibitor that is especially effective against the T315I mutation for the treatment of chronic myeloid leukemia. FDA approved on December 14, 2012. | Moderate | 1 | [
[
[
980,
24,
1468
]
],
[
[
980,
63,
589
],
[
589,
24,
1468
]
],
[
[
980,
24,
987
],
[
987,
63,
1468
]
],
[
[
980,
24,
850
],
[
850,
... | [
[
[
"Tocilizumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ponatinib"
]
],
[
[
"Tocilizumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cisplatin"
],
[
... | Tocilizumab may cause a moderate interaction that could exacerbate diseases when taken with Cisplatin and Cisplatin may cause a moderate interaction that could exacerbate diseases when taken with Ponatinib
Tocilizumab may cause a moderate interaction that could exacerbate diseases when taken with Vibrio cholerae CVD 10... |
DB00570 | DB00827 | 147 | 646 | [
"DDInter1936",
"DDInter383"
] | Vinblastine | Cinoxacin | Antitumor alkaloid isolated from Vinca rosea. (Merck, 11th ed.) | Synthetic antimicrobial related to oxolinic acid and nalidixic acid and used in urinary tract infections. | Minor | 0 | [
[
[
147,
23,
646
]
],
[
[
147,
21,
28722
],
[
28722,
60,
646
]
],
[
[
147,
24,
77
],
[
77,
62,
646
]
],
[
[
147,
63,
322
],
[
322,
2... | [
[
[
"Vinblastine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Cinoxacin"
]
],
[
[
"Vinblastine",
"{u} (Compound) causes {v} (Side Effect)",
"Nausea"
],
[
"Nausea",
"{u} (Side Effect) is caused by {... | Vinblastine (Compound) causes Nausea (Side Effect) and Nausea (Side Effect) is caused by Cinoxacin (Compound)
Vinblastine may cause a moderate interaction that could exacerbate diseases when taken with Idarubicin and Idarubicin may cause a minor interaction that can limit clinical effects when taken with Cinoxacin
Vinb... |
DB00500 | DB08880 | 24 | 1,510 | [
"DDInter1831",
"DDInter1771"
] | Tolmetin | Teriflunomide | A non-steroidal anti-inflammatory agent (anti-inflammatory agents, NON-steroidal) similar in mode of action to indomethacin. | Teriflunomide is the active metabolite of leflunomide, and it acts as an immunomodulatory agent by inhibiting pyrimidine synthesis. It is marketed under the name Aubagio® and is indicated for the treatment of multiple sclerosis, specifically relapsing forms. The FDA label states an important warning about the risk of h... | Major | 2 | [
[
[
24,
25,
1510
]
],
[
[
24,
24,
1144
],
[
1144,
24,
1510
]
],
[
[
24,
63,
1061
],
[
1061,
24,
1510
]
],
[
[
24,
23,
752
],
[
752,
... | [
[
[
"Tolmetin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Teriflunomide"
]
],
[
[
"Tolmetin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nateglinide"
],
[
"Nateglinid... | Tolmetin may cause a moderate interaction that could exacerbate diseases when taken with Nateglinide and Nateglinide may cause a moderate interaction that could exacerbate diseases when taken with Teriflunomide
Tolmetin may cause a moderate interaction that could exacerbate diseases when taken with Treprostinil and Tre... |
DB09052 | DB10315 | 250 | 1,137 | [
"DDInter220",
"DDInter1127"
] | Blinatumomab | Measles virus vaccine live attenuated | Blinatumomab is a BiTE-class (bi-specific T-cell engager) constructed monoclonal antibody formed by the recombinant fusion of an anti-CD3 single-chain variable fragment (scFV) and an anti-CD19 scFV through a short peptide linker.[A254836,L44311] CD3 is an antigen expressed on the surface of T-cells, while CD19 is mostl... | Measles virus vaccine live attenuated is a live virus vaccine for simultaneous vaccination against measles, which is a common childhood disease. The vaccine is prepared from the attenuated line of measles virus, derived from Enders' attenuated Edmonston strain and propagated in chick embryo cell culture. | Major | 2 | [
[
[
250,
25,
1137
]
],
[
[
250,
64,
581
],
[
581,
25,
1137
]
],
[
[
250,
24,
384
],
[
384,
25,
1137
]
],
[
[
250,
63,
1184
],
[
1184,
... | [
[
[
"Blinatumomab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Measles virus vaccine live attenuated"
]
],
[
[
"Blinatumomab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Infliximab"
],
[
... | Blinatumomab may lead to a major life threatening interaction when taken with Infliximab and Infliximab may lead to a major life threatening interaction when taken with Measles virus vaccine live attenuated
Blinatumomab may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib and Idela... |
DB00242 | DB00975 | 1,064 | 1,317 | [
"DDInter392",
"DDInter573"
] | Cladribine | Dipyridamole | An antineoplastic agent used in the treatment of lymphoproliferative diseases including hairy-cell leukemia. | A phosphodiesterase inhibitor that blocks uptake and metabolism of adenosine by erythrocytes and vascular endothelial cells. Dipyridamole also potentiates the antiaggregating action of prostacyclin. (From AMA Drug Evaluations Annual, 1994, p752) | Moderate | 1 | [
[
[
1064,
24,
1317
]
],
[
[
1064,
21,
28936
],
[
28936,
60,
1317
]
],
[
[
1064,
24,
477
],
[
477,
63,
1317
]
],
[
[
1064,
64,
305
],
[
305... | [
[
[
"Cladribine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dipyridamole"
]
],
[
[
"Cladribine",
"{u} (Compound) causes {v} (Side Effect)",
"Hyperhidrosis"
],
[
"Hyperhidrosis",
"{u} (Side Effec... | Cladribine (Compound) causes Hyperhidrosis (Side Effect) and Hyperhidrosis (Side Effect) is caused by Dipyridamole (Compound)
Cladribine may cause a moderate interaction that could exacerbate diseases when taken with Cilostazol and Cilostazol may cause a moderate interaction that could exacerbate diseases when taken wi... |
DB00704 | DB00766 | 267 | 1,675 | [
"DDInter1263",
"DDInter394"
] | Naltrexone | Clavulanic acid | Derivative of noroxymorphone that is the N-cyclopropylmethyl congener of naloxone. It is a narcotic antagonist that is effective orally, longer lasting and more potent than naloxone, and has been proposed for the treatment of heroin addiction. The FDA has approved naltrexone for the treatment of alcohol dependence. | Clavulanic acid is a beta-lactamase inhibitor that is frequently combined with [Amoxicillin] or [Ticarcillin] to fight antibiotic resistance by preventing their degradation by beta-lactamase enzymes, broadening their spectrum of susceptible bacterial infections. Clavulanic acid is derived from the organism Streptomyces... | Moderate | 1 | [
[
[
267,
24,
1675
]
],
[
[
267,
21,
29058
],
[
29058,
60,
1675
]
],
[
[
267,
24,
850
],
[
850,
63,
1675
]
],
[
[
267,
63,
482
],
[
482,
... | [
[
[
"Naltrexone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clavulanic acid"
]
],
[
[
"Naltrexone",
"{u} (Compound) causes {v} (Side Effect)",
"Hepatitis"
],
[
"Hepatitis",
"{u} (Side Effect) is... | Naltrexone (Compound) causes Hepatitis (Side Effect) and Hepatitis (Side Effect) is caused by Clavulanic acid (Compound)
Naltrexone may cause a moderate interaction that could exacerbate diseases when taken with Brentuximab vedotin and Brentuximab vedotin may cause a moderate interaction that could exacerbate diseases ... |
DB01097 | DB10316 | 1,377 | 334 | [
"DDInter1033",
"DDInter1248"
] | Leflunomide | Mumps virus strain B level jeryl lynn live antigen | Leflunomide is a pyrimidine synthesis inhibitor belonging to the DMARD (disease-modifying antirheumatic drug) class of drugs, which are chemically and pharmacologically very heterogeneous. Leflunomide was approved by FDA and in many other countries (e.g., Canada, Europe) in 1999. | Mumps virus strain B level jeryl lynn live antigen is a live attenuated virus vaccine for subcutenous injection. It is an active immunization against mumps, which is a common childhood disease. | Major | 2 | [
[
[
1377,
25,
334
]
],
[
[
1377,
25,
1042
],
[
1042,
24,
334
]
],
[
[
1377,
25,
594
],
[
594,
25,
334
]
],
[
[
1377,
64,
1057
],
[
1057,
... | [
[
[
"Leflunomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Mumps virus strain B level jeryl lynn live antigen"
]
],
[
[
"Leflunomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tetracosactide"... | Leflunomide may lead to a major life threatening interaction when taken with Tetracosactide and Tetracosactide may cause a moderate interaction that could exacerbate diseases when taken with Mumps virus strain B level jeryl lynn live antigen
Leflunomide may lead to a major life threatening interaction when taken with B... |
DB00555 | DB01069 | 706 | 401 | [
"DDInter1020",
"DDInter1533"
] | Lamotrigine | Promethazine | Lamotrigine is an antiepileptic drug belonging in the phenyltriazine class. It is used in the treatment of both epilepsy and as a mood stabilizer in bipolar disorder. Lamotrigine is the first medication since lithium granted Food and Drug Administration (FDA) approval for the maintenance treatment of bipolar type I. It... | Promethazine, originally known as 3,277 R.P., is an N-dimethylaminopropyl derivative of [phenothiazine] that was developed in France in 1946. Promethazine antagonizes a variety of receptors, allowing it to be used for a number of indications including allergic reactions, pain, sedation, nausea, and vomiting.[A189907,A1... | Moderate | 1 | [
[
[
706,
24,
401
]
],
[
[
706,
24,
1264
],
[
1264,
63,
401
]
],
[
[
706,
6,
4973
],
[
4973,
45,
401
]
],
[
[
706,
21,
28709
],
[
28709,
... | [
[
[
"Lamotrigine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Promethazine"
]
],
[
[
"Lamotrigine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxepin"
],
[
... | Lamotrigine may cause a moderate interaction that could exacerbate diseases when taken with Doxepin and Doxepin may cause a moderate interaction that could exacerbate diseases when taken with Promethazine
Lamotrigine (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Promethazine (Compound)
Lamotrigine (Compoun... |
DB01404 | DB09075 | 757 | 498 | [
"DDInter820",
"DDInter621"
] | Ginseng | Edoxaban | Ginseng is promoted as an adaptogen (a product that increases the body's resistance to stress), one which can to a certain extent be supported with reference to its anticarcinogenic and antioxidant properties. Ginseng is also known to contain phytoestrogens. | Edoxaban is a member of the Novel Oral Anti-Coagulants (NOACs) class of drugs, and is a rapidly acting, oral, selective factor Xa inhibitor. By inhibiting factor Xa, a key protein in the coagulation cascade, edoxaban prevents the stepwise amplification of protein factors needed to form blood clots. It is indicated to r... | Moderate | 1 | [
[
[
757,
24,
498
]
],
[
[
757,
63,
582
],
[
582,
25,
498
]
],
[
[
757,
24,
256
],
[
256,
25,
498
]
],
[
[
757,
24,
1421
],
[
1421,
6... | [
[
[
"Ginseng",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Edoxaban"
]
],
[
[
"Ginseng",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Reteplase"
],
[
"Rete... | Ginseng may cause a moderate interaction that could exacerbate diseases when taken with Reteplase and Reteplase may lead to a major life threatening interaction when taken with Edoxaban
Ginseng may cause a moderate interaction that could exacerbate diseases when taken with Prasugrel and Prasugrel may lead to a major li... |
DB00312 | DB01176 | 1,023 | 537 | [
"DDInter1423",
"DDInter453"
] | Pentobarbital | Cyclizine | A short-acting barbiturate that is effective as a sedative and hypnotic (but not as an anti-anxiety) agent and is usually given orally. It is prescribed more frequently for sleep induction than for sedation but, like similar agents, may lose its effectiveness by the second week of continued administration. (From AMA Dr... | A histamine H1 antagonist given by mouth or parenterally for the control of postoperative and drug-induced vomiting and in motion sickness. (From Martindale, The Extra Pharmacopoeia, 30th ed, p935) | Moderate | 1 | [
[
[
1023,
24,
537
]
],
[
[
1023,
24,
1242
],
[
1242,
24,
537
]
],
[
[
1023,
24,
104
],
[
104,
1,
537
]
],
[
[
1023,
21,
28930
],
[
28930,
... | [
[
[
"Pentobarbital",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cyclizine"
]
],
[
[
"Pentobarbital",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cetirizine"
],
... | Pentobarbital may cause a moderate interaction that could exacerbate diseases when taken with Cetirizine and Cetirizine may cause a moderate interaction that could exacerbate diseases when taken with Cyclizine
Pentobarbital may cause a moderate interaction that could exacerbate diseases when taken with Methdilazine and... |
DB01087 | DB04946 | 1,520 | 924 | [
"DDInter1520",
"DDInter907"
] | Primaquine | Iloperidone | An aminoquinoline that is given by mouth to produce a radical cure and prevent relapse of vivax and ovale malarias following treatment with a blood schizontocide. It has also been used to prevent transmission of falciparum malaria by those returning to areas where there is a potential for re-introduction of malaria. Ad... | Iloperidone is an atypical antipsychotic for the treatment of schizophrenia symptoms. Hoechst Marion Roussel Inc. researched the drug until May 1996. In June 1997 they gave the research rights to Titan Pharmaceuticals, who gave the worldwide development, manufacturing, and marketing rights to Novartis in August 1998. O... | Major | 2 | [
[
[
1520,
25,
924
]
],
[
[
1520,
63,
1664
],
[
1664,
1,
924
]
],
[
[
1520,
64,
1425
],
[
1425,
25,
924
]
],
[
[
1520,
24,
519
],
[
519,
... | [
[
[
"Primaquine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Iloperidone"
]
],
[
[
"Primaquine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Risperidone"
],
[
"Risperid... | Primaquine may cause a moderate interaction that could exacerbate diseases when taken with Risperidone and Risperidone (Compound) resembles Iloperidone (Compound)
Primaquine may lead to a major life threatening interaction when taken with Cisapride and Cisapride may lead to a major life threatening interaction when tak... |
DB00791 | DB08908 | 132 | 713 | [
"DDInter1902",
"DDInter564"
] | Uracil mustard | Dimethyl fumarate | Nitrogen mustard derivative of uracil. It is a alkylating antineoplastic agent that is used in lymphatic malignancies, and causes mainly gastrointestinal and bone marrow damage. | Dimethyl fumarate is an agent indicated for the treatment of relapsing forms of multiple sclerosis.[A253942,L43752] The mechanism of action of dimethyl fumarate in multiple sclerosis is not well understood. It is thought to involve dimethyl fumarate degradation to its active metabolite monomethyl fumarate (MMF) then MM... | Moderate | 1 | [
[
[
132,
24,
713
]
],
[
[
132,
24,
4
],
[
4,
24,
713
]
],
[
[
132,
24,
270
],
[
270,
63,
713
]
],
[
[
132,
1,
970
],
[
970,
24,
... | [
[
[
"Uracil mustard",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dimethyl fumarate"
]
],
[
[
"Uracil mustard",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Omacetaxine ... | Uracil mustard may cause a moderate interaction that could exacerbate diseases when taken with Omacetaxine mepesuccinate and Omacetaxine mepesuccinate may cause a moderate interaction that could exacerbate diseases when taken with Dimethyl fumarate
Uracil mustard may cause a moderate interaction that could exacerbate d... |
DB00307 | DB00615 | 1,101 | 690 | [
"DDInter202",
"DDInter1589"
] | Bexarotene | Rifabutin | Bexarotene (Targretin) is an antineoplastic agent indicated by the FDA for Cutaneous T cell lymphoma. It has been used off-label for lung cancer, breast cancer, and Kaposi's sarcoma. | A broad-spectrum antibiotic that is being used as prophylaxis against disseminated Mycobacterium avium complex infection in HIV-positive patients. | Minor | 0 | [
[
[
1101,
23,
690
]
],
[
[
1101,
23,
463
],
[
463,
1,
690
]
],
[
[
1101,
6,
8374
],
[
8374,
45,
690
]
],
[
[
1101,
21,
29062
],
[
29062,
... | [
[
[
"Bexarotene",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Rifabutin"
]
],
[
[
"Bexarotene",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Rifampicin"
],
[
"... | Bexarotene may cause a minor interaction that can limit clinical effects when taken with Rifampicin and Rifampicin (Compound) resembles Rifabutin (Compound)
Bexarotene (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Rifabutin (Compound)
Bexarotene (Compound) causes Neutropenia (Side Effect) and Neutropenia... |
DB01181 | DB06168 | 1,532 | 1,531 | [
"DDInter906",
"DDInter281"
] | Ifosfamide | Canakinumab | Ifosfamide is a chemotherapeutic agent chemically related to the nitrogen mustards and a synthetic analog of cyclophosphamide. It is active as an alkylating agent and an immunosuppressive agent. | Canakinumab is a recombinant, human anti-human-IL-1β monoclonal antibody that belongs to the IgG1/κ isotype subclass. It is expressed in a murine Sp2/0-Ag14 cell line and comprised of two 447- (or 448-) residue heavy chains and two 214-residue light chains, with a molecular mass of 145157 Daltons when deglycosylated. B... | Moderate | 1 | [
[
[
1532,
24,
1531
]
],
[
[
1532,
63,
1461
],
[
1461,
23,
1531
]
],
[
[
1532,
63,
523
],
[
523,
24,
1531
]
],
[
[
1532,
24,
1270
],
[
1270... | [
[
[
"Ifosfamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Canakinumab"
]
],
[
[
"Ifosfamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vitamin E"
],
[
... | Ifosfamide may cause a moderate interaction that could exacerbate diseases when taken with Vitamin E and Vitamin E may cause a minor interaction that can limit clinical effects when taken with Canakinumab
Ifosfamide may cause a moderate interaction that could exacerbate diseases when taken with Alprazolam and Alprazola... |
DB00978 | DB14491 | 739 | 428 | [
"DDInter1084",
"DDInter725"
] | Lomefloxacin | Ferrous fumarate | Lomefloxacin is a fluoroquinolone antibiotic, used to treat bacterial infections including bronchitis and urinary tract infections (UTIs). Additionally, it has been employed for the prophylaxis of UTIs prior to surgery as well. | Used in treatment of iron deficiency anemia. | Moderate | 1 | [
[
[
739,
24,
428
]
],
[
[
739,
24,
1096
],
[
1096,
23,
428
]
],
[
[
739,
1,
246
],
[
246,
24,
428
]
],
[
[
739,
40,
1176
],
[
1176,
... | [
[
[
"Lomefloxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ferrous fumarate"
]
],
[
[
"Lomefloxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mycophenolic acid... | Lomefloxacin may cause a moderate interaction that could exacerbate diseases when taken with Mycophenolic acid and Mycophenolic acid may cause a minor interaction that can limit clinical effects when taken with Ferrous fumarate
Lomefloxacin (Compound) resembles Gatifloxacin (Compound) and Gatifloxacin may cause a moder... |
DB00004 | DB01155 | 669 | 872 | [
"DDInter499",
"DDInter813"
] | Denileukin diftitox | Gemifloxacin | A recombinant DNA-derived cytotoxic protein composed of the amino acid sequences for diphtheria toxin fragments A and B (Met 1-Thr 387)-His followed by the sequences for interleukin-2 (IL-2; Ala 1-Thr 133). It is produced in an E. coli expression system. | Gemifloxacin is a quinolone antibacterial agent with a broad-spectrum activity that is used in the treatment of acute bacterial exacerbation of chronic bronchitis and mild-to-moderate pneumonia. It is available in oral formulations. Gemifloxacin acts by inhibiting DNA synthesis through the inhibition of both DNA gyrase... | Minor | 0 | [
[
[
669,
23,
872
]
],
[
[
669,
23,
739
],
[
739,
1,
872
]
],
[
[
669,
23,
945
],
[
945,
40,
872
]
],
[
[
669,
25,
770
],
[
770,
24,
... | [
[
[
"Denileukin diftitox",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Gemifloxacin"
]
],
[
[
"Denileukin diftitox",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Lomefloxaci... | Denileukin diftitox may cause a minor interaction that can limit clinical effects when taken with Lomefloxacin and Lomefloxacin (Compound) resembles Gemifloxacin (Compound)
Denileukin diftitox may cause a minor interaction that can limit clinical effects when taken with Sparfloxacin and Sparfloxacin (Compound) resemble... |
DB00738 | DB04946 | 485 | 924 | [
"DDInter1420",
"DDInter907"
] | Pentamidine | Iloperidone | Antiprotozoal agent effective in trypanosomiasis, leishmaniasis, and some fungal infections; used in treatment of pneumocystis pneumonia in HIV-infected patients. It may cause diabetes mellitus, central nervous system damage, and other toxic effects. | Iloperidone is an atypical antipsychotic for the treatment of schizophrenia symptoms. Hoechst Marion Roussel Inc. researched the drug until May 1996. In June 1997 they gave the research rights to Titan Pharmaceuticals, who gave the worldwide development, manufacturing, and marketing rights to Novartis in August 1998. O... | Major | 2 | [
[
[
485,
25,
924
]
],
[
[
485,
63,
1664
],
[
1664,
1,
924
]
],
[
[
485,
64,
1425
],
[
1425,
25,
924
]
],
[
[
485,
24,
519
],
[
519,
... | [
[
[
"Pentamidine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Iloperidone"
]
],
[
[
"Pentamidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Risperidone"
],
[
"Risper... | Pentamidine may cause a moderate interaction that could exacerbate diseases when taken with Risperidone and Risperidone (Compound) resembles Iloperidone (Compound)
Pentamidine may lead to a major life threatening interaction when taken with Cisapride and Cisapride may lead to a major life threatening interaction when t... |
DB08901 | DB11703 | 1,468 | 405 | [
"DDInter1492",
"DDInter9"
] | Ponatinib | Acalabrutinib | Ponatinib is a novel Bcr-Abl tyrosine kinase inhibitor that is especially effective against the T315I mutation for the treatment of chronic myeloid leukemia. FDA approved on December 14, 2012. | To date, acalabrutinib has been used in trials studying the treatment of B-All, myelofibrosis, ovarian cancer, multiple myeloma, and Hodgkin lymphoma, among others. As of October 31, 2017 the FDA approved Astra Zeneca's orally administered Calquence (acalabrutinib, capsules). This Bruton tyrosine kinase (BTK) inhibitor... | Major | 2 | [
[
[
1468,
25,
405
]
],
[
[
1468,
23,
1384
],
[
1384,
24,
405
]
],
[
[
1468,
63,
1051
],
[
1051,
24,
405
]
],
[
[
1468,
64,
1101
],
[
1101,... | [
[
[
"Ponatinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Acalabrutinib"
]
],
[
[
"Ponatinib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Magaldrate"
],
[
"Magaldrate"... | Ponatinib may cause a minor interaction that can limit clinical effects when taken with Magaldrate and Magaldrate may cause a moderate interaction that could exacerbate diseases when taken with Acalabrutinib
Ponatinib may cause a moderate interaction that could exacerbate diseases when taken with Aminoglutethimide and ... |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.